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The Surgical Infection Society Guidelines on
Antimicrobial Therapy for Intra-Abdominal Infections:
Evidence for the Recommendations
JOHN E. MAZUSKI,1 ROBERT G. SAWYER,2 AVERY B. NATHENS,3 JOSEPH T. DIPIRO,4
MOSHE SCHEIN,5 KENNETH A. KUDSK,6 and CHARLES YOWLER7 FOR THE
THERAPEUTIC AGENTS COMMITTEE OF THE SURGICAL INFECTION SOCIETY
ABSTRACT
Revised guidelines for the use of antimicrobial therapy in patients with intra-abdominal in-
fections were recently developed by the Therapeutic Agents Committee of the Surgical In-
fection Society (Mazuski et al., Surg Infect 2002;3:161–173). These were based, insofar as pos-
sible, on evidence published over the past decade. The objective of this document is to
describe the process by which the Committee identified and reviewed the published litera-
ture utilized to develop the recommendations and to summarize the results of those reviews.
English-language articles published between 1990 and 2000 related to antimicrobial therapy
for intra-abdominal infections were identified by a systematic MEDLINE search and an ex-
amination of references included in recent review articles. If current literature with regard to
a specific issue was lacking, relevant articles published prior to 1990 were identified. All
prospective randomized controlled trials, as well as other articles selected by the Committee,
were evaluated individually and collectively. Data with regard to patient numbers, types of
infections, and results of interventions were abstracted. Studies were categorized according
to their design, and all included trials were graded according to quality. On the basis of this
evidence, the Committee formulated recommendations for antimicrobial therapy for intra-ab-
dominal infections and graded those recommendations. After receiving comments from in-
vited reviewers and the general membership of the Society, the guidelines were finalized and
submitted to the Council of the Surgical Infection Society for approval. The final recom-
mendations related to the selection of patients needing therapeutic antimicrobials, acceptable
antimicrobial regimens, duration of antimicrobial use, and the identification and treatment
of higher-risk patients. Although numerous publications pertaining to these topics were 
identified, but nearly all of the prospective randomized controlled trials represented com-
parisons of different antimicrobial regimens for the treatment of intra-abdominal infections.
A few prospective trials evaluated the need for therapeutic antimicrobial therapy in patients
with peritoneal contamination following abdominal trauma. The quality of these prospective
trials was highly variable. Many did not limit enrollment to patients with complicated intra-
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INTRODUCTION
IN 1992, the Antimicrobial Agents Committee(now the Therapeutic Agents Committee) of
the Surgical Infection Society (SIS) published
guidelines for the use of antimicrobial agents
in patients with intra-abdominal infections [1].
These guidelines defined the types of infections
that required antimicrobial therapy, character-
ized the bacteria likely to be involved in those
infections, described the general principles for
the use of antimicrobials, and recommended
specific antimicrobial agents or combination
regimens which were considered appropriate
for treatment. The Therapeutic Agents Com-
mittee of the SIS has recently updated the orig-
inal guidelines published in 1992, primarily us-
ing literature published since 1990 [2]. These
revised guidelines represent an extension, but
not a replacement of the original guidelines de-
veloped by Bohnen et al. [1].
In undertaking this revision, the Committee
set as an additional goal the formal catego-
rization of its recommendations according to
current principles of evidence-based medicine.
Although there is no universally accepted sys-
tem for describing clinical evidence or recom-
mendations [3], most authors employ termi-
nology similar to that originally developed by
the Canadian Task Force on the Periodic Health
Evaluation [4]. Using this methodology, the
published studies used to create recommenda-
tions are first categorized according to study
design and quality, and then, in turn, the rec-
ommendations developed from these studies
are graded according to the strength of evi-
dence behind them.
In this article, we will first describe the
processes by which the Committee selected and
evaluated the literature relevant to these guide-
lines, and integrated these data to formulate the
recommendations regarding antimicrobial
therapy for patients with intra-abdominal in-
fections. Then, the actual evidence used in de-
veloping the guidelines will be detailed sepa-
rately with regard to the four major topics
reviewed: (1) the selection of patients requiring
therapeutic antimicrobials; (2) the duration of
antimicrobial therapy; (3) appropriate antimi-
crobial regimens for treatment of patients with
intra-abdominal infections; and (4) the identi-
fication and treatment of higher-risk patients
for whom initial therapy of their infections is
likely to fail.
GUIDELINE DEVELOPMENT
The initial impetus for the development of
these revised guidelines came at the meeting of
the Therapeutic Agents Committee in May
2000, following a directive from the Council of
the SIS that the Committee undertake a for-
malized process of guideline development and
review. The Committee proposed that a high
priority be given to revising the previous posi-
tion paper of the Society on the use of antimi-
crobial therapy for patients with intra-abdom-
inal infections, since this document had not
been revisited in nearly ten years, and was an
issue of importance to the membership of the
Society at large. The proposal to revise these
guidelines was formally accepted by the Coun-
cil in October 2000, with the Therapeutic
Agents Committee directed to serve as the ex-
pert panel for this revision.
The initial deliberations of the Committee fo-
cused on the approach to be used in revising
the previous guidelines. Over the past decade,
the “science” of guideline development has un-
dergone considerable evolution, and many or-
ganizations have produced guidelines related
abdominal infections, lacked blinding of treatment assignment, did not provide a complete
description of the criteria used to determine therapeutic success or failure, failed to identify
the reasons why patients were excluded from analysis, or did not include an intention-to-treat
analysis. For many issues, no prospective randomized controlled trials were encountered, and
guidelines had to be formulated using evidence from studies with historical controls or un-
controlled data, or on the basis of expert opinion.
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to clinical issues. Among surgical organiza-
tions, the Eastern Association for the Surgery
of Trauma (EAST) has been at the forefront in
developing guidelines for the treatment of pa-
tients with surgical problems. Their approach
to guideline development has been described
in detail [5]. The Committee therefore selected
this approach as its model for the preparation
of these revised guidelines. The steps recom-
mended by the EAST in guideline development
are outlined in Table 1.
Scope of the guidelines
The Committee first sought to define the
types of patients with intra-abdominal infec-
tions that would be covered by these guide-
lines, and then to identify specific questions to
be addressed. In general, the Committee chose
to restrict its focus to surgical patients with in-
tra-abdominal infections, that is, those gener-
ally described as secondary or tertiary peri-
tonitis, or intra-abdominal abscesses. Patients
who would not be covered by these guidelines
included those with primary peritonitis and 
infections associated with indwelling intra-
abdominal catheters, and those with infections
related to primary gynecological or genitouri-
nary disorders. Patients with localized infec-
tions of an abdominal organ for which no pri-
mary source control procedure was performed,
such as patients with acute diverticulitis or
cholecystitis treated non-operatively, would
also not be covered by the proposed recom-
mendations. Thus, these guidelines would ap-
ply to patients described as having complicated
intra-abdominal infections, that is, those re-
quiring a surgical or radiologically guided pro-
cedure for control of the infection [6]. These re-
strictions are quite similar to those used
previously by Bohnen et al. [1].
In the initial discussions, the Committee also
decided not to attempt a complete revision of
the previous guidelines of Bohnen et al. [1].
Many of their descriptions, such as those re-
lated to the pathogenesis and microbiology of
intra-abdominal infections, were still up to date
and did not need revising. Instead, the Com-
mittee chose to focus on several treatment-re-
lated issues that had engendered discussion
both in the published literature as well as at So-
ciety meetings during the past decade. Each is-
sue was to be reviewed initially by a two- or
three-member working group of the Commit-
tee, and then by the Committee as a whole. The
issues and questions that were selected for dis-
cussion fell into four general areas:
Patient selection. Which patients should be
treated with antimicrobials for intra-abdominal
infections? What distinguishes intra-abdomi-
nal contamination from an established intra-ab-
dominal infection? Are prolonged courses of
antimicrobials warranted in patients who have
contamination only? What constitutes prophy-
lactic, as opposed to therapeutic, use of an-
timicrobials for intra-abdominal infections?
Duration of antimicrobial therapy. What is the
optimal duration of antimicrobial therapy for
patients with intra-abdominal infections? Can
this be specified based on the type of intra-ab-
dominal infection? Should clinical symptoms
and signs be used to guide duration of antimi-
crobial therapy?
Recommended antimicrobial regimens. Which
antimicrobial regimens can be recommended
for the treatment of patients with intra-ab-
dominal infections? Are any of these regimens
of greater or lesser efficacy? Can oral antimi-
crobials be utilized in patients with intra-ab-
dominal infections? How should aminoglyco-
sides be utilized in these patients?
Identification and treatment of the higher risk pa-
tient. What risk factors identify patients likely
TABLE 1. DEVELOPMENT OF CLINICAL
PRACTICE GUIDELINES
Step Procedure
1 Topic selection
2 Selection of a panel
3 Clarification of purpose and scope of the
guidelines
4 Listing of goals and specification of questions
5 Assessment (grading) of scientific evidence
6 Establishing the recommendations
7 Drafting and validation of the document
8 Presentation
9 Implementation
10 Validation
Adapted from Pasquale [5].
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to experience failure of initial therapy? Can the
antimicrobial regimen be intensified in such
patients to decrease the risk of failure? Should
higher–risk patients be treated empirically for
enterococcal or fungal organisms? How should
patients with tertiary peritonitis be treated?
Selection of the literature for review
In order to obtain the best evidence with
which to address these questions, the Commit-
tee undertook a systematic search for all Eng-
lish-language articles on the use of antimicro-
bials for intra-abdominal infections published
between 1990 and 2000. The 1990 limit was se-
lected because the relevant literature up to 1990
had been available to the authors of the previ-
ous guidelines. The MEDLINE database was
searched using multiple strategies, in which the
names of specific antimicrobials or more gen-
eral descriptors (e.g., cephalosporins) were
paired with words and phrases indicating an
intra-abdominal infection (e.g., peritonitis, in-
tra-abdominal abscess, appendicitis). This ini-
tial search included studies that were in the
MEDLINE database as of December 4, 2000.
At the outset, one goal of the Committee was
to develop a database of all prospective ran-
domized controlled trials published during this
time period that related to the use of antimi-
crobial therapy for the treatment of intra-ab-
dominal infections. These publications were
believed to provide the best evidence for po-
tential guidelines. Therefore, all abstracts ob-
tained from this initial search strategy were
screened in an effort to identify any publica-
tion that might feature this trial design. To un-
cover additional prospective randomized con-
trolled trials missed by this screening process,
the references of a number of authoritative re-
view articles discussing treatment of intra-ab-
dominal infections [7–19] were also examined.
A search of the Cochrane Database of Systematic
Reviews [20] was also performed, but this failed
to identify additional relevant publications.
All articles identified by this initial screening
process then received a preliminary review.
Studies that were not prospective randomized
controlled trials were excluded from the data-
base. However, those publications could still be
used for the development of specific recom-
mendations if an individual working group be-
lieved that the study contained information 
relevant to the specific topic. In addition,
prospective trials that examined prophylactic,
but not therapeutic, use of antimicrobials, ad-
ministered to patients who did not have es-
tablished intra-abdominal infections were also
eliminated from further consideration.
All remaining prospective randomized con-
trolled trials were then reviewed by at least one
member of the Committee to determine their
suitability for inclusion in the database. Stud-
ies could be excluded from further considera-
tion for several reasons established by the
Committee. The decision to exclude any given
prospective trial had to be confirmed by a con-
sensus of the Committee as a whole. A few re-
ports were excluded because they were found
to be duplicate publications of the same trial.
Under these circumstances, the publication that
more thoroughly described the trial was in-
cluded in the database. In addition, some trials
enrolled patients with indications for antimi-
crobial use other than intra-abdominal infec-
tions. These other indications included pneu-
monia, bacteremia, and soft tissue infections.
Generally, the Committee utilized such trials
only if the clinical efficacy in patients with in-
tra-abdominal infections was described sepa-
rately from the overall group of patients, and
there were at least 30 evaluable patients with
intra-abdominal infections for whom data were
available. A few studies permitted administra-
tion of additional antimicrobials on the basis of
physician discretion, without any clear criteria
for their use being specified in the protocol.
These studies were excluded from the database
if the final efficacy determination was obscured
by the inclusion of such patients. Finally, some
trials enrolled patients who did not undergo
operative therapy of their intra-abdominal in-
fections, and many studies included patients
who did not need prolonged antimicrobial
therapy for established infections, according to
the previous criteria of Bohnen et al. [1] and the
Infectious Disease Society of America (IDSA)
guidelines [6]. Patients in this latter category
included those with simple appendicitis or
cholecystitis, and those with recent traumatic
intestinal perforations or gastroduodenal per-
forations. Ultimately, the Committee chose to
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include most of these studies in the database,
as long as it appeared that the majority of
evaluable patients had positive peritoneal cul-
tures or diagnoses of complicated intra-ab-
dominal infections requiring therapeutic an-
timicrobial therapy. However, studies in which
most or all patients could have been treated
with short-term antimicrobial therapy were ex-
cluded.
Not surprisingly, many facets of antimicro-
bial therapy for intra-abdominal infections
were not addressed by prospective random-
ized controlled trials. Therefore, other studies
that appeared relevant to the development of
these guidelines were also selected from the
body of literature identified during this screen-
ing process. Priority for review was given to
epidemiological studies and investigations that
utilized some type of controlled design, al-
though articles expressing the opinions of ex-
perts in the field were also collected. The deci-
sions to select additional studies for review was
left to the working groups developing those ar-
eas of the guidelines, and ultimately approved
by the Committee as a whole.
For some topics, there was a paucity of evi-
dence published after 1990. Therefore, the in-
dividual working groups identified prospec-
tive randomized controlled trials and other
studies published prior to 1990 that could be
used to supplement the data obtained from
later investigations. The prospective trials were
included in the database, but a formal, sys-
tematic search to identify all such studies pub-
lished prior to 1990 was not performed.
Evaluation of the evidence
The prospective randomized controlled tri-
als selected for inclusion in the database, and
all other studies judged to be relevant to the
development of the guidelines were reviewed
fully by at least one, and usually two members
of the Committee. Details were abstracted with
regard to the specific topic investigated, the
study design, the types of patients entered and
excluded from the study, and the results of the
treatment interventions. The study design was
classified using the nomenclature outlined by
the EAST [5], and supplemented by descrip-
tions utilized by the American Society for Par-
enteral and Enteral Nutrition [21] (Table 2). Es-
sentially, Class I evidence was that obtained
from prospective randomized controlled trials
or meta-analyses of those trials, Class II evi-
dence was that obtained from other prospec-
tive and retrospective controlled studies con-
taining clearly reliable data, and Class III
evidence was that obtained from uncontrolled
studies, case reports, and expert opinion.
All prospective randomized controlled trials
were further graded for quality using the sys-
tem devised by Jadad et al. [22] (Table 3). This
assessment assigns a quality score of 0–5 based
on the adequacy of randomization, blinding,
and description of patients excluded from the
study. Reproducibility of the quality ratings
was determined by having second members of
the Committee, blinded to the first reviewers’
scores, grade most studies. Replicate quality
scores were nearly always within one point of
each other, and no major discrepancies were
identified. Minor discrepancies between the re-
viewers were resolved between the individual
Committee members. Since no generally ac-
cepted system exists for assessing the quality
of Class II and Class III evidence, these studies
were not graded objectively.
The quality scores determined from these re-
views proved to be quite low. Only about 20%
of the trials received a score of 4 or 5; an addi-
tional 20% received a score of 3. The median
quality score for all prospective trials was less
than 2.
Among the individual components of the
quality scores, randomization appeared to be
adequate in nearly all the studies, and most tri-
als were given 1 or 2 points toward the overall
quality score. However, fewer than 30% of the
trials were given any points for blinding, since
most were not designed as double-blind trials.
There were descriptions in some publications
of attempts to obtain blinded assessments of
outcome even though the study was designed
as an open-label trial. Generally, these trials
still did not meet the criteria specified by Jadad
et al. [22] to ensure that they were free from
bias.
The final point of the quality rating is deter-
mined by how the investigators have described
patients excluded from the trial after random-
ization. Both the reasons for exclusions, and the
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numbers of patients excluded for each reason
need to be detailed. The Committee identified
this as a particular area of concern. Fully one-
third of the publications provided an inade-
quate description of excluded patients. How-
ever, there were problems even among the
studies that received credit for providing the
necessary information. It became apparent that
the criteria cited by the various investigators
for excluding patients, that is, defining the clin-
ically evaluable population, varied widely.
Some of these criteria seemed quite arbitrary.
In some trials, patients were excluded auto-
matically if they were found subsequently to
have a resistant organism isolated at the time
of operative intervention, regardless of the re-
sults of initial empiric antimicrobial therapy.
Others excluded patients who suffered adverse
reactions to study drugs, even if they were
switched to different antimicrobial agents be-
cause of the adverse reaction. In addition, some
studies excluded patients who developed noso-
comial infections outside of the abdominal cav-
ity that required subsequent antimicrobial ther-
apy. Although the final outcome in some of
these patients is truly indeterminate, both the
IDSA [6] and the SIS [23] guidelines for the de-
sign of these antimicrobial trials indicate that
most of these patients can be considered evalu-
able, as long as success or failure of the ther-
apy of the intra-abdominal infection is appar-
ent at the time treatment of the nosocomial
infection is initiated.
Many studies, as alluded to above, included
patients in the final analysis who should have
been excluded, because they did not have com-
plicated intra-abdominal infections requiring
antimicrobial therapy for greater than 24 h. Ex-
amples of such patients included those whose
infections had not been confirmed with posi-
tive peritoneal cultures, those who had diag-
noses not requiring prolonged antimicrobial
therapy, such as non-perforated appendicitis,
and those who had conditions such as recent
gastroduodenal perforation suggestive of intra-
abdominal contamination but not infection. In
addition, a few studies included limited num-
bers of patients with gynecological, perirectal,
or abdominal wound infections, or patients
who were treated non-operatively for an intra-
abdominal process such as acute diverticulitis.
Unfortunately, the inclusions of such patients
in the clinically evaluable populations limit the
usefulness of these trials for determining opti-
mal antimicrobial therapy of patients with
complicated intra-abdominal infections.
TABLE 2. CLASSIFICATION OF EVIDENCE
Class Evidence
I Prospective randomized controlled trials or meta-analyses of such trials.
II Prospective studies without randomization or other studies in which data were collected
prospectively, and retrospective analyses based on clearly reliable data. These include
observational studies, cohort studies, prevalence studies, and retrospective case control studies.
III Uncontrolled studies using retrospective data, such as clinical series or case reviews, and expert
opinion.
Adapted from Pasquale [5] and Wolfe and Mathiesen [21].
TABLE 3. QUALITY SCORING OF PROSPECTIVE RANDOMIZED CONTROLLED TRIALS
Randomization: Score one point if the study was described as randomized. Add one additional point if the
method of randomization was described, and was appropriate (e.g., random number table, computer-generated
list). Subtract one point if the method of randomization was inappropriate (e.g., alternate allocation, date of birth,
hospital number).
Double blinding: Score one point if the study was described as double blind. Add one additional point if the
method of double blinding was described and was appropriate (e.g., identical placebo, active placebo, dummy).
Subtract one point if the method of blinding was inappropriate (e.g., no double dummy for comparison of an oral
versus an injectable medication).
Withdrawals and dropouts: Score one point if the reasons why randomized patients were withdrawn from
analysis were described, and the numbers of patients withdrawn for each reason were specified.
Adapted from Jadad et al. [22].
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In reviewing all the evidence, the Commit-
tee attempted to apply a common descriptor of
outcome to the data obtained from prospective
trials. Most investigators reported a clinical
success or clinical failure rate in evaluable pa-
tients. The Committee generally chose to use
the investigators’ reported clinical success
rates, or recalculated clinical success rates
when necessary, as its common measure of out-
come.
For a number of reasons, however, the re-
ported clinical success rates were not readily
comparable across the various studies. As dis-
cussed above, investigators used different cri-
teria to exclude patients from the final analy-
sis, which changes the denominator used to
calculate success rates. Of perhaps greater im-
portance, investigators utilized different crite-
ria to describe clinical successes and failures,
which affects the numerator used in these cal-
culations. Unfortunately, in some publications,
the authors failed to specify exactly the criteria
that were used to determine clinical success or
failure. Moreover, many investigators did not
utilize standards similar to those suggested by
the IDSA and SIS [6,23] for evaluating clinical
outcome in trials of antimicrobial therapy for
intra-abdominal infections.
Many different examples of the variable defi-
nitions of clinical success or failure were en-
countered. In a number of studies, clinical fail-
ure was defined as the persistence of symptoms
or signs of infection after a limited time period,
whether or not a different antimicrobial treat-
ment regimen was implemented. The SIS and
IDSA guidelines indicate that these patients
should be considered clinical treatment failures
if additional antimicrobial therapy is utilized
or another source control procedure is neces-
sary to treat ongoing infection. As indicated
previously, patients who developed nosoco-
mial infections outside of the abdomen were
also variably described. In some studies, these
patients were considered successfully treated,
in others, they were counted as treatment fail-
ures, and in still others, they were excluded
from the final analysis. Also, in a few studies,
patients with adverse events requiring a
change to other antimicrobial agents were re-
ported as treated successfully or were excluded
from the final analysis, although these patients
should generally be reported as having failed
the initial antimicrobial treatment regimen.
Another problem with the reported success
rates was the lack of uniformity in the timing
of outcome reporting. In general, final outcome
should be determined several weeks after the
end of antimicrobial therapy, and patients for
whom there is incomplete follow-up data
should be considered unevaluable. In a num-
ber of publications, however, there was no in-
dication as to when success or failure was de-
termined. Other authors reported success rates
only at the end of therapy, or provided only in-
complete follow-up data after the end of ther-
apy. In a few studies, it was apparent that pa-
tient outcomes had changed during subsequent
follow-up, and that success rates reported at
the end of therapy had been overstated. Nev-
ertheless, the incomplete follow-up informa-
tion made it impossible to verify the accuracy
of success rates determined at later time points.
Therefore, success rates reported at the end of
therapy were used as the final measure of out-
come in these studies if they were the only ones
available that were based on an assessment of
the entire clinically evaluable population.
Although it might have been desirable to re-
classify patient outcomes to bring them more
into line with the SIS and IDSA criteria [6,23],
this would rarely have been possible because
of the limited descriptions of unsuccessful clin-
ical outcomes provided in most publications.
Ultimately, the Committee accepted most of
the investigators’ reported success rates at face
value, and only modified them for a few se-
lected reasons to improve uniformity. If the in-
vestigators had not already done so, patients
who were given a final outcome of “improved”
or some similar adjective were included among
the successfully treated patients in recalculat-
ing clinical success rates. Patients designated as
“improved” generally required no further an-
timicrobial therapy, although they might not
have completely resolved all symptoms and
signs of infection. The Committee also recalcu-
lated some success rates by excluding patients
with indeterminate outcomes from the denom-
inator, if this had not already been done. In a
few studies, no clinical success or failure rate
was reported, but a description of the adverse
outcomes that occurred in patients enrolled in
182 MAZUSKI ET AL.
the study was provided. For these studies, the
success rate was calculated as best as possible
using the available information.
Interpretations of outcome were also influ-
enced strongly by the manner in which inves-
tigators reported surgical site infections
(“wound infections”). Most studies counted
such patients as therapeutic failures, which is
consistent with the IDSA and SIS criteria [6,23].
In some trials, though, patients with superficial
surgical site infections were considered to be
treated successfully as long as no other com-
plications occurred. Since the development and
identification of superficial surgical site infec-
tions in patients with intra-abdominal infec-
tions may relate more to surgical decisions re-
garding wound closure than to the utility of a
specific antimicrobial regimen, it has been rec-
ommended that adverse outcomes due only to
superficial surgical site infections be reported
separately from other failures [24].
In some of these studies, in fact, virtually all
the clinical failures were due to “wound in-
fections.” In order to evaluate more serious
failures apart from those due to superficial
surgical site infections, when possible, the
Committee determined the rates of these in-
fections from the information available in the
publications. Further, the Committee calcu-
lated additional clinical success rates in which
patients with isolated superficial surgical site
infections were not counted as treatment fail-
ures. For these calculations to be valid, how-
ever, the numbers of patients who failed ther-
apy exclusively because of superficial surgical
site infections had to be unambiguously
stated. In calculating these additional success
rates, patients with deep surgical site infec-
tions, and patients who had reasons aside
from superficial surgical site infections for
failing therapy were still considered as un-
successfully treated. Although these recalcu-
lated success rates are clearly subject to inter-
pretational error, they do provide an
additional measure with which to compare
different trials of antimicrobial therapy for in-
tra-abdominal infections, particularly when
superficial surgical site infections account for
many of the reported adverse outcomes.
By considering the outcome in all patients,
an intention-to-treat (ITT) analysis helps en-
sure that issues related to patient exclusions
and indeterminate outcomes have not unduly
biased study results. In a few of the trials of
antimicrobials for intra-abdominal infections,
an ITT analysis was provided. In other trials,
a modified ITT analysis was performed. For
these modified ITT analyses, patients might be
excluded because they did not have an intra-
abdominal infection identified at the time of
surgical intervention, or they did not receive
study medications for some reason. Unfortu-
nately, most publications did not include the
results of either an ITT or a modified ITT
analysis. Many times, only the results obtained
from the clinically evaluable patients were re-
ported.
Other reviewers [24,25] have previously
identified many of the same problems in trial
design, implementation, and interpretation
that were prevalent in the publications re-
viewed by the Committee. Overall, though, it
appeared that trial quality had improved some-
what over the decade. Several recent large
multi-institutional trials were conducted ac-
cording to the principles outlined by the IDSA
and SIS. Nevertheless, for the database as a
whole, relatively poor quality data was the rule
rather than the exception. Although potentially
desirable, the Committee did not believe that it
would be possible to rely exclusively on the
larger, higher-quality studies for developing
guidelines without limiting greatly the scope of
the recommendations.
Ultimately, the Committee attempted to in-
tegrate the evidence in the database by using
investigators’ reported success rates in clini-
cally evaluable patients as a means of compar-
ing outcome across studies. Where available,
the results of recalculated success rates ex-
cluding patients who failed therapy because of
superficial surgical site infections and the re-
sults of ITT analyses were also utilized. How-
ever, the Committee recognizes that the inter-
pretation of these success rates is problematic
because of the numerous methodological is-
sues described above. Therefore, these reported
clinical success rates can only be used as a
rough guide to the utility of various interven-
tions, particularly when such interventions
have not been compared directly in prospec-
tive trials.
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Formulation and approval of the guidelines
Based on this and other evidence, the indi-
vidual working groups drafted provisional
guidelines in their particular area of investiga-
tion, and graded those recommendations. For
grading, the Committee chose the relatively
simple system outlined by the EAST [5], sup-
plemented by descriptions employed by the
American Society for Parenteral and Enteral
Nutrition (Table 4) [21]. Although this grading
system is less complex than others, it still al-
lows a straightforward characterization of the
evidence behind each recommendation. Level
1 guidelines are those having good research-
based evidence to support the recommenda-
tion, which usually requires relatively homo-
geneous Class I evidence. Generally, the
Committee required consistent evidence from
at least two prospective randomized controlled
trials to justify a Level 1 recommendation.
Level 2 guidelines are based on reasonable re-
search-based evidence, which may indicate
some heterogeneity in the results of prospec-
tive randomized controlled trials, or the need
to rely primarily on Class II evidence to sup-
port the recommendation. Level 3 guidelines are
those based on Class III evidence and expert
opinion. Although Level 1 guidelines can be
considered standards of care, the evidence be-
hind recommendations classified as Level 2 or
Level 3 is insufficient for them to be so consid-
ered. Level 3 recommendations, in particular,
identify issues that should be addressed by ad-
ditional prospective randomized controlled tri-
als or other rigorously-conducted studies.
The entire Committee then refined the rec-
ommendations drafted by each working group
through a process of iterative consensus. A con-
sensus on the grading of each recommendation
was also reached. A preliminary draft of the
guidelines and the evidence behind them was
then submitted to two independent reviewers
from the Society, who were not members of the
Committee. The proposed guidelines were pre-
sented at the 21st Annual Meeting of the SIS
(May 3–5, 2001, Snowbird, UT), following
which the two discussants provided their in-
depth critiques of the recommendations. An
open forum was also held to allow the general
membership of the Society to comment on the
proposed guidelines.
These critiques and discussions were then
used to modify the guidelines into their pres-
ent form. After final consensus was achieved,
the Committee submitted these guidelines
along with supporting materials to the Coun-
cil of the SIS. The Council has approved these
guidelines as the official position of the SIS
with respect to antimicrobial therapy for pa-
tients with intra-abdominal infections.
PATIENT SELECTION
Most patients undergoing abdominal proce-
dures receive antimicrobials in the periopera-
tive period. Much of this use is intended as pro-
phylaxis, primarily to prevent surgical site
infections. Prophylactic antimicrobials seldom
should be used for longer than 24 h; a single
dose of antibiotic is sufficient for most proce-
dures. The use of prophylactic antimicrobials
is not covered under these guidelines.
The decision to treat a patient with thera-
peutic (non-prophylactic) antimicrobials re-
TABLE 4. RATING SCALE FOR RECOMMENDATIONS
Level Recommendation
1 Recommendation based on good research-based evidence. Supported primarily by homogeneous,
prospective, randomized controlled trials, although strong Class II data may be the basis of
the
recommendation when the issue is not amenable to study with a prospective randomized
controlled trial.
2 Recommendation based on fair research-based evidence. Supported by limited data from 
prospective, randomized controlled trials, or from other prospective or retrospective
analyses with good study design, and strongly supported by expert opinion.
3 Recommendation based primarily on limited or uncontrolled data and supported by expert
opinion.
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quires that an established intra-abdominal in-
fection be present. Therapeutic antimicrobials
are defined here as those that are given for
greater than 24 h. To fulfill the diagnosis of an
established intra-abdominal infection, not only
must a normally sterile area of the abdominal
cavity be contaminated with infectious mater-
ial, but also an inflammatory focus must have
become established because of that microbial
inoculum. From the perspective of the surgeon,
this corresponds to an infected site that cannot
be eradicated completely with the primary
source control procedure.
The presence of infectious material, which is
a prerequisite for the development of an intra-
abdominal infection, is usually apparent at the
time of the initial source control procedure. An
obvious bowel perforation or the presence of en-
teric fluid implies that contamination with in-
fectious material has occurred. Occasionally,
purulent peritoneal fluid without an obvious en-
teric source is identified, and it may be less clear
that infectious material is actually present. Un-
der these circumstances, Gram stain and culture
of the fluid may be performed to determine if
microorganisms are actually present, although
these tests prove ambiguous on occasion.
Contamination of the abdominal cavity by
microorganisms is not in itself synonymous
with an established intra-abdominal infection.
The duration of the contamination and the in-
tensity of the reaction must be sufficient to al-
low for the development of an inflammatory
focus. The abdominal cavity probably needs to
be exposed to infectious material for at least
12–24 h to allow an intra-abdominal infection
to become established. The source and quan-
tity of the infectious material contaminating the
abdomen influences greatly the size of the 
microbial inoculum, and thereby the rapidity
with which an infection develops. Nonetheless,
there are no absolute criteria for determining if
intra-abdominal contamination has progressed
to an established infection. Ultimately, the clin-
ician must use the clinical history, radiographic
examinations, and direct intra-operative obser-
vations to make this judgment.
The issue as to whether or not an established
intra-abdominal infection is present generates
much of the controversy regarding the selec-
tion of patients for therapeutic antimicrobial
therapy. There are clearly patients who fall into
the gray area between contamination and es-
tablished infection. Such patients include those
who sustained heavy intra-abdominal contam-
ination before or during an operative proce-
dure, and those who have an infected focus
within the abdominal cavity confined to a spe-
cific organ that can be eradicated by an opera-
tive procedure. The need for therapeutic an-
timicrobials in such patients should be based, in
as much as possible, on the results of prospec-
tive studies of antimicrobial therapy carried out
in similar patients.
Summary of findings
By far the best evidence concerning which
patients need therapeutic antimicrobials comes
from studies of patients with traumatic bowel
perforations. Based on studies available at the
time, Bohnen et al. [1] recommended that pa-
tients with traumatic bowel perforations oper-
ated on within 12 h receive 24 h or less of an-
timicrobial therapy. Three large prospective
randomized controlled trials published in the
past decade have provided additional evidence
to support that recommendation. These stud-
ies compared the use of short-term versus
longer-term antimicrobial therapy in patients
with penetrating abdominal trauma [26–28].
Two of these studies [26,28] were restricted to
patients with hollow viscus injuries as a result
of penetrating trauma. Nearly half of the pa-
tients in the third study also had such injuries
[27]. In the three studies combined, 852 patients
were evaluated who had been randomized to
receive 24 h versus 5 days of perioperative an-
tibiotics. There were no significant differences
between the two study groups in any of the tri-
als with respect to the numbers of patients de-
veloping intra-abdominal infections, which av-
eraged 6–10% in both groups (Table 5). The
total numbers of infections, including those
outside the abdomen, also did not appear to be
influenced by the duration of antimicrobial
treatment. Thus, in patients with penetrating
abdominal trauma and hollow viscus injury,
there does not seem to be any benefit to the use
of prolonged antimicrobial therapy, and pro-
phylactic antibiotics administered for 24 h or
less are appropriate for these patients.
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It is important to note that all patients in
these trials underwent surgical therapy fairly
soon after the injury was sustained. Patients
who were not operated on early or had missed
injuries were excluded from these studies. The
guidelines of Bohnen et al. [1] recommended
short-term antimicrobial therapy only for those
patients whose perforations had been treated
surgically within 12 h. Although this time point
was not directly ascertained on the basis of
prospective data, it still represents a reasonable
estimate of the time required for major conta-
mination to evolve into an established infec-
tion.
Although these trials enrolled only patients
with penetrating abdominal trauma, it seems
reasonable to apply the results to other patient
groups. Examples of such patients include
those who have sustained hollow viscus in-
juries as a result of blunt trauma and those who
have received an iatrogenic bowel injury, such
as a colonoscopic perforation of the colon.
Again, this consideration would apply only if
the operative procedure was performed expe-
ditiously. These results should also apply to pa-
tients who have inadvertent enteric contami-
nation during elective abdominal procedures,
since the short duration of contamination
should not result in an established infection. In
these additional patient groups it seems un-
likely that prolonged exposure to antimicro-
bials would produce a clinical benefit that was
not evident in patients who had sustained pen-
etrating hollow viscus injury.
Because of the low numbers of bacteria nor-
mally found in the stomach and duodenum,
perforations of the gastrointestinal tract above
the ligament of Treitz generally result in much
less intra-abdominal contamination than per-
forations of the distal small bowel or colon.
Bohnen et al. [1] indicated that patients with
gastroduodenal perforations less than 24 h old
did not need to be treated with therapeutic an-
timicrobials. Although a definitive study of this
has not been performed, very limited data and
expert opinions indicate that gastroduodenal
perforations repaired early require less than 
24 h of antimicrobial therapy [29–31].
Patients who had an infected focus that could
be eradicated fully at the time of surgical in-
tervention also do not require therapeutic an-
timicrobials, according to the previous guide-
lines [1]. Examples of these patients include
those with non-perforated appendicitis, acute
or gangrenous cholecystitis, or bowel necrosis
without perforation. Treatment of such patients
with prophylactic antimicrobial therapy was
examined in two series of patients. Andåker et
al. [29] described 147 patients with acute or
gangrenous appendicitis, 18 patients with
cholecystitis, and 52 patients with small bowel
or colonic obstructions who were treated with
antimicrobials for 24 h or less. Clinical success
rates in these three groups of patients were 98%,
100%, and 90%, respectively (Table 6). Schein et
al. [30] described a series of 92 patients, among
whom were 55 with acute or gangrenous ap-
pendicitis, 21 with acute or gangrenous chole-
cystitis, and four with small bowel necrosis
without perforation. These patients were treated
according to a protocol specifying a maximum
of 24 h of perioperative antibiotics. There were
no major intra-abdominal infectious complica-
tions in these patients, and only 4% of the pa-
tients developed superficial surgical site infec-
tions (Table 6). Overall, infection rates in both
of these series were comparable to those found
in contemporary literature. Thus, there is rea-
sonable evidence that antimicrobial therapy
can be limited to 24 h or less in patients with
acute or gangrenous appendicitis, acute or gan-
grenous cholecystitis, and those with bowel ob-
struction or bowel necrosis due to a vascular
accident or strangulation, in whom there is no
evidence of perforation (Table 7). However,
these recommendations do not apply to pa-
tients whose infection has extended beyond the
initial anatomic focus and who have purulent,
infected, peritoneal fluid. Since these patients
have established intra-abdominal infections,
therapeutic antimicrobial therapy is warranted.
The guidelines regarding patient selection for
use of therapeutic antimicrobials are summa-
rized in Table 8.
DURATION OF 
ANTIMICROBIAL THERAPY
Although patients who do not have estab-
lished intra-abdominal infections can be
treated with antimicrobials for 24 h or less, the
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optimal duration of antimicrobial therapy for
patients with established intra-abdominal in-
fections remains controversial. There is very lit-
tle Class I evidence that can be used to evalu-
ate this topic, and expert opinions vary widely.
In many prospective trials, duration of therapy
has been left to the discretion of the investiga-
tor. Thus, antimicrobial therapy has been per-
mitted for 3–14 days or more, and few criteria
have been specified for eventual discontinua-
tion of antimicrobials.
There is little agreement even with regard to
the clinical determinants that should be used
in establishing optimal duration of treatment.
Some recommend that a fixed duration of an-
timicrobial therapy be designated at the time
of the initial surgical intervention, based on the
specific pathological findings. Others advocate
continuation of antimicrobial therapy until the
patient’s symptoms and signs of infection have
resolved. Still others promote a combined ap-
proach.
One difficulty in determining the optimal
duration of therapy is that a remarkably di-
verse number of conditions are described as
intra-abdominal infections. These vary from
relatively minor infections, such as a peri-ap-
pendiceal abscess, to severe infections, such as
a massive retroperitoneal infection associated
with extensive peri-pancreatic necrosis. Pa-
tients with the former conditions might be
treated adequately with very short courses of
antimicrobials, whereas patients with the lat-
ter conditions might need more prolonged
therapy. In fact, it may be impossible to
achieve adequate source control in patients
with these latter conditions, and antimicrobial
therapy may ultimately be unsuccessful, re-
gardless of its duration.
One potential approach to the diversity of
conditions described as intra-abdominal infec-
tions would be to utilize systems that stratify
patients according to the type and source of in-
fection, such as that outlined by Meakins et al.
[32]. Such systems could define cohorts of pa-
tients for investigations of optimal duration of
antimicrobial therapy. Unfortunately, such
stratification schemes have not been used
widely in clinical trials up to now.
Thus, there has not yet been a sufficiently
powered, prospective randomized controlled
clinical trial performed that has evaluated ad-
equately the duration of antimicrobial therapy
for patients with intra-abdominal infections.
This lack of data may be explained by the lo-
gistical difficulties of studying this complex
population of patients, as well as the lack of a
commercial incentive to carry out such trials,
whose results might lead to decreased use of
antimicrobials. The evidence that can be used
to formulate recommendations on this topic,
therefore, is limited to that obtained from small
prospective studies, retrospective studies, and
expert opinions.
Summary of findings
There is a growing consensus that prolonged
courses of antimicrobial agents are not necessary
for many patients with intra-abdominal infec-
tions. In the previous guidelines, Bohnen et al.
[1] recommended 5–7 days of antimicrobial ther-
TABLE 7. CONDITIONS FOR WHICH THERAPEUTIC
ANTIMICROBIALS (.24 H) ARE NOT RECOMMENDED
Traumatic and iatrogenic enteric perforations operated
on within 12 h.
Gastroduodenal perforations operated on within 24 h.
Acute or gangrenous appendicitis without perforation.
Acute or gangrenous cholecystitis without perforation.
Transmural bowel necrosis from embolic, thrombotic, or
obstructive vascular occlusion without perforation or
established peritonitis or abscess.
TABLE 8. GUIDELINES FOR SELECTION OF PATIENTS
WHO REQUIRE THERAPEUTIC (.24 H) VERSUS
PROPHYLACTIC ANTIMICROBIALS (,24 H)
1. Patients with peritoneal contamination due to
traumatic or iatrogenic bowel injuries repaired
within 12 h (Level 1), and those having
gastroduodenal perforations less than 24 h old
(Level 3) are not considered to have established
intra-abdominal infections, and should be treated
with prophylactic antimicrobials for 24 h or less.
2. Patients with a fully removable focus of
inflammation, such as those with acute or
gangrenous, but non-perforated appendicitis or
cholecystitis, and those with bowel necrosis or
obstruction without perforation or peritonitis, should
be treated with prophylactic antimicrobials for 24 h
or less (Level 2).
3. Patients with more extensive conditions than those
noted above should be treated as having established
infections, and given therapeutic antimicrobials for
greater than 24 h (Level 3).
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apy for most patients. More recently, Wittmann
and Schein [31] proposed even shorter durations
of therapy. Although there are no Class I stud-
ies addressing this issue specifically, some evi-
dence supporting shorter duration of antimi-
crobial use can be gleaned from reports of
protocols that limited the duration of therapy
based on the initial operative findings. In the
study described previously by Andåker et al.
[27], antimicrobials were limited to 5 days in a
cohort of 84 patients with intra-abdominal in-
fections. Similarly, in the study by Schein et al.
[28] antimicrobials were limited to 48 h in 48 pa-
tients with localized peritonitis, and to three to
five days in 23 patients with diffuse peritonitis.
In both studies, the reported success rates for
these patients ranged from 83%–100% (Table 6).
These success rates are comparable to those re-
ported in contemporary literature for patients
with similar disease processes, who generally re-
ceived longer courses of antimicrobials.
As an alternative to a fixed duration of ther-
apy, antimicrobials could be discontinued when
the patient’s symptoms and signs of infection
resolve. The risk of treatment failure appears to
be quite low in patients who have no clinical
evidence of infection at the time of cessation of
antimicrobial therapy [33,34]. This usually im-
plies that the patient’s temperature and white
blood cell count has normalized, and bowel
function has returned. In a Class II study by
Smith et al. [35], patients with peritonitis from
appendiceal and non-appendiceal sources had
antimicrobials discontinued after four days of
therapy if clinical evidence of infection had
abated. Compared to historical controls, these
patients received fewer doses of antibiotics and
had no increase in infectious complications
(Table 9). In a prospective randomized con-
trolled trial, Taylor et al. [36] evaluated the need
for prolonged antimicrobial therapy in two
groups of patients with complicated appendici-
tis. In one group, all patients received a mini-
mum of 5 days of intravenous antibiotics, but
in the second group, no minimum duration of
antibiotic therapy was specified. Eventual dis-
continuation of antibiotics in both groups was
based on clinical criteria. The duration of an-
tibiotic use was significantly longer in the group
assigned to a minimum of 5 days of antimicro-
bial therapy, but there was no difference be-
tween the two groups in the numbers of infec-
tious complications. Thus, limiting the duration
of antimicrobial therapy on the basis of clinical
signs and symptoms seems reasonable accord-
ing to the evidence provided by these studies.
Unfortunately, this conclusion is clouded some-
what because many of the patients in these
studies did not need prolonged antimicrobial
therapy, as they had gangrenous appendicitis
or intra-abdominal contamination only.
Although these data suggest that antimicro-
bial therapy can be limited in patients with in-
tra-abdominal infections who show improve-
ments in their clinical signs and symptoms, they
do not address the problematic patient who
does not show similar improvements after a
prescribed course of antimicrobials. Several in-
vestigators have determined that patients with
persistent clinical evidence of infection at the
time of discontinuation of antimicrobials are
likely to develop subsequent infectious compli-
cations. Studies by Lennard et al. [33,34], among
others, identified persistent fever and leukocy-
tosis as predictors of clinical failure.
When patients have persistent clinical signs
of infection, the tendency of many clinicians is
to prolong the course of antimicrobial therapy,
using the same or different agents. However,
there are few, if any data demonstrating that
this approach improves patient outcome. In
fact, Lennard et al. [33,34] did not advocate
such an approach. In their studies, most of the
patients with persistent clinical signs of infec-
tion were eventually found to have a new or
recurrent intra-abdominal infection. Thus, they
felt that a search for the source of the persis-
tent clinical signs, along with an appropriate
procedure to adequately control that source,
would have ultimately been much more bene-
ficial than either prolongation of the same an-
timicrobial therapy or a change to other agents.
However, there is some evidence that a more
prolonged course of antimicrobials is war-
ranted in certain highly selected patients.
Visser et al. [37] analyzed retrospectively a se-
ries of patients managed using an open ab-
dominal technique because of refractory peri-
tonitis. Decreased duration of antimicrobial
treatment was identified as a risk factor for 
failure in these patients. The authors recom-
mended that antimicrobials not be discontin-
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ued in such patients if there was ongoing clin-
ical evidence of infection. It seems reasonable
to utilize a longer course of antimicrobial ther-
apy in similar patients in whom it is difficult
or impossible to achieve primary source con-
trol. However, such considerations apply to
only a small number of patients, such as those
with infected peri-pancreatic necrosis, in whom
an adequate primary source control procedure
may not be feasible, or those with tertiary peri-
tonitis, who have repeatedly failed previous
therapeutic efforts.
Based on the limited data and the opinions
of members of the SIS, therefore, the Commit-
tee recommends that antimicrobial therapy be
limited to no more than five to seven days for
most patients with complicated intra-abdomi-
nal infections (Table 10). It seems reasonable to
base the maximum duration of antimicrobial
therapy on the extent of the infection identified
at the time of the initial source control proce-
dure, and to discontinue therapy when clinical
symptoms and signs of infection abate. In pa-
tients with persistent clinical evidence of in-
fection after the completion of a predetermined
course of antimicrobial therapy, an attempt
should be made to determine the source of that
problem. Patients with persistent or recurrent
intra-abdominal infections are unlikely to re-
spond just to prolongation of antibiotic therapy
with the same or a modified regimen, but
rather will likely require additional therapeu-
tic efforts to achieve definitive source control.
Patients with nosocomial infections at extra-ab-
dominal sites will need appropriate antimicro-
bial therapy directed at those problems. If a pa-
tient has persistent clinical symptoms and signs,
but no evidence of a new or persistent infection
is uncovered after a careful investigation, a trial
observation off all antimicrobial therapy is war-
ranted, since the persistent clinical symptoms
and signs may be the result of ongoing sterile
tissue inflammation or drug-induced hyper-
thermia, and not due to infection [31]. However,
it is prudent to monitor carefully such patients
for  recurrent intra-abdominal infection, which
could still develop.
ANTIMICROBIAL REGIMENS FOR
INTRA-ABDOMINAL INFECTIONS
The fundamental principles of antimicrobial
therapy for intra-abdominal infections were
outlined over 25 years ago, and have not
changed substantially in the interim. These
principles were based on experimental models
of intra-abdominal infections and subsequent
clinical studies, which demonstrated that an-
timicrobial regimens should cover common
aerobic/facultatively anaerobic Enterobacteri-
aceae such as Escherichia coli, and anaerobic or-
ganisms, particularly Bacteroides fragilis [38,39].
Although the initial regimens shown to be ef-
ficacious included an aminoglycoside, such as
gentamicin, combined with an antianaerobic
agent, such as clindamycin, the repertoire of
antimicrobial agents has expanded greatly over
the past two decades, and many single agents
or combination regimens are now available for
the treatment of patients with intra-abdominal
infections.
In the previous guidelines, Bohnen et al. [1]
identified second-generation cephalosporins
with anaerobic coverage (cefoxitin, cefotetan,
cefmetazole), ticarcillin/clavulanic acid, and
imipenem/cilastatin as acceptable single-agent
therapy. Appropriate combination regimens
included an aminoglycoside (gentamicin, to-
bramycin, netilmicin, or amikacin) plus an 
antianaerobic agent (clindamycin or metron-
idazole), a third-generation cephalosporin (ce-
fotaxime, ceftizoxime, ceftazidime, or ceftriax-
TABLE 10. GUIDELINES FOR THE DURATION
OF ANTIMICROBIAL THERAPY FOR ESTABLISHED
INTRA-ABDOMINAL INFECTIONS
1. Antimicrobial therapy of most established intra-
abdominal infections should be limited to no more
than 5 (Level 2) to 7 days (Level 3). The duration of
antimicrobial therapy for intra-abdominal infections
can be based on the intra-operative findings at the
time of initial intervention (Level 3). Antimicrobial
therapy can be discontinued in patients when they
have no clinical evidence of infection such as fever
or leukocytosis (Level 2).
2. Continued clinical evidence of infection at the end
of the time period designated for antimicrobial
therapy should prompt appropriate diagnostic
investigations rather than prolongation of
antimicrobial treatment (Level 3).
3. If adequate source control cannot be achieved, a
longer duration of antimicrobial therapy may be
warranted (Level 3).
SIS AND INTRA-ABDOMINAL INFECTIONS: EVIDENCE 193
one) plus an antianaerobic agent, and aztre-
onam plus clindamycin for the treatment of
patients with intra-abdominal infections.
Over the past decade, a number of prospec-
tive randomized controlled trials have evalu-
ated further these agents, as well as others
such as ampicillin/sulbactam, piperacillin/
tazobactam, meropenem, ertapenem, and ce-
furoxime, cefepime, ciprofloxacin combined
with metronidazole, for which little definitive
information was available prior to 1990. The re-
sults of these and selected earlier trials are sum-
marized individually in Table 11, to which the
reader is referred during the subsequent dis-
cussions of specific antimicrobial regimens.
The Committee used this body of Class I data,
supplemented by limited amounts of Class II
and Class III data, to expand the list of accept-
able antimicrobial regimens for the treatment
of patients with complicated intra-abdominal
infections.
Ideally, these data would identify those an-
timicrobial agents most effective for treating in-
tra-abdominal infections. The Committee could
then designate those agents as preferred or
first-line therapy for this indication. However,
the Committee found it impossible to make
such determinations on the basis of therapeu-
tic superiority. Few trials reported a statisti-
cally significant difference in outcome between
treatment arms, and those that did so tended
to be smaller, lower-quality studies. Moreover,
in several studies, the observed differences in
outcome were related primarily to rates of su-
perficial surgical site infections, and not to
more serious infectious complications. In gen-
eral, the larger, higher-quality studies demon-
strated few statistically significant differences
in outcome between different regimens.
A further problem with designating pre-
ferred antimicrobial regimens was that very
few of the trials were actually designed to de-
tect therapeutic superiority. Many investiga-
tors did not include a power analysis in their
descriptions of trial design, that is, there was
no estimate of the number of patients that
would be needed to detect a specific difference
between the treatment groups. Among those
that did provide this information, the trials
were usually powered only to detect thera-
peutic equivalence, or more correctly, non-in-
feriority, and not therapeutic superiority. Thus,
many of these trials were only designed to de-
tect a true difference of greater than 10–15% be-
tween treatment arms.
The technique of meta-analysis can be used
to combine the results of studies that individ-
ually are powered insufficiently to detect mea-
surable differences in outcome. In actuality,
however, the Committee found that very few
meta-analyses related to antimicrobial therapy
for patients with intra-abdominal infections.
Although the Committee did utilize the re-
ported and calculated clinical success rates as
a rough guide to compare the results of differ-
ent therapeutic regimens, this was done with-
out undertaking a formal meta-analytic review.
In any case, the results of such meta-analyses
would have to have been interpreted with ex-
treme caution, since the component trials had
such widely varying design and quality.
In the end, the Committee concluded that the
information from the database could be used
to identify effective antimicrobial regimens for
the treatment of patients with intra-abdominal
infections, but not to specify therapeutically su-
perior regimens. Preference for one regimen
over another would need to be based on crite-
ria other than the therapeutic efficacies re-
ported in the published literature.
Another issue that proved problematic for
the Committee was the applicability of these
antimicrobial recommendations to different
groups of patients with intra-abdominal in-
fections. To evaluate this, the Committee re-
viewed the diagnoses of the clinically evalu-
able patients enrolled in the various trials.
Overall, it appeared that most of the patients
had relatively easy-to-treat community-ac-
quired infections, such as complicated ap-
pendicitis. In fact, in ten trials, enrollment
was limited to such patients, and in many
others, the majority of the evaluable patients
had an appendiceal source of infection. The
conclusion that most patients enrolled in
these studies were less severely ill was con-
firmed by the relatively low mortality rates
found in most trials, as will be discussed sub-
sequently. Therefore, the recommendations
outlined in this section pertain primarily to
the treatment of lower-risk patients with
community-acquired intra-abdominal infec-
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 s
of
t 
ti
ss
u
e 
in
fe
ct
io
ns
.
10
Si
gn
if
ic
an
tl
y 
d
if
fe
re
nt
  
( p
5
0.
00
6)
 i
n 
fa
vo
r 
of
 c
ef
op
er
az
on
e/
su
lb
ac
ta
m
.
E
rt
ap
en
em
32
3
20
3
87
%
3%
90
%
79
%
83
6%
14
61
%
[1
04
]
1 
g 
qd
85
So
lo
m
ki
n,
P
ip
er
ac
ill
in
/
4
Y
es
2
Y
es
in
 p
re
ss
ta
zo
ba
ct
am
31
0
19
3
81
%
4%
85
%
76
%
83
4%
14
59
%
3.
37
5 
g 
q6
h8
5
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11
T
hr
ee
 p
at
ie
nt
s 
in
 t
he
 c
lin
ic
al
ly
 e
va
lu
ab
le
 p
op
u
la
ti
on
 h
ad
 s
of
t 
ti
ss
u
e 
in
fe
ct
io
ns
.
12
A
ft
er
 t
he
 i
ni
ti
al
 d
os
e,
 s
u
bs
eq
u
en
t 
to
br
am
yc
in
 d
os
in
g 
w
as
 b
as
ed
 o
n 
ph
ar
m
ac
ok
in
et
ic
 c
al
cu
la
ti
on
s 
an
d 
se
ru
m
 d
ru
g 
co
nc
en
tr
at
io
ns
.
13
Su
cc
es
s 
ra
te
s 
w
er
e 
ca
lc
ul
at
ed
 a
ft
er
 e
xc
lu
d
in
g 
p
at
ie
nt
s 
w
it
h 
in
d
et
er
m
in
at
e 
ou
tc
om
es
.
14
M
or
ta
lit
y 
ra
te
s 
w
er
e 
ba
se
d
 o
n 
al
l p
at
ie
nt
s 
en
ro
lle
d
 i
n 
th
e 
st
u
d
y.
15
U
se
 o
f 
va
nc
om
yc
in
 w
as
 p
er
m
it
te
d
 f
or
 p
at
ie
nt
s 
th
ou
gh
t 
to
 h
av
e 
re
si
st
an
t 
G
ra
m
-p
os
it
iv
e 
or
ga
ni
sm
s.
16
Si
gn
if
ic
an
tl
y 
d
if
fe
re
nt
 (
p
5
0.
04
) 
in
 f
av
or
 o
f 
im
ip
en
em
/
ci
la
st
at
in
.
17
M
ed
ia
n 
A
P
A
C
H
E
 I
I 
sc
or
es
 w
er
e 
pr
ov
id
ed
 f
or
 d
if
fe
re
nt
 d
ia
gn
os
es
.
18
Pe
d
ia
tr
ic
 d
os
in
g.
19
Pa
ti
en
ts
 e
nr
ol
le
d
 in
cl
ud
ed
 c
hi
ld
re
n 
2 
ye
ar
s 
of
 a
ge
 o
r 
ol
d
er
 a
nd
 a
d
u
lt
 p
at
ie
nt
s.
20
C
hi
ld
re
n 
10
 y
ea
rs
 o
f 
ag
e 
an
d
 y
ou
ng
er
 r
ec
ei
ve
d
 t
he
 h
ig
he
r 
ge
nt
am
ic
in
 d
os
e.
21
A
ll 
p
at
ie
nt
s 
en
ro
lle
d
 w
er
e 
ch
ild
re
n 
18
 y
ea
rs
 o
f 
ag
e 
an
d
 y
ou
ng
er
.
22
H
ig
he
r 
d
os
es
 a
nd
/
or
 s
ho
rt
er
 d
os
in
g 
in
te
rv
al
s 
w
er
e 
u
se
d
 f
or
 p
at
ie
nt
s 
w
it
h 
se
ri
ou
s 
or
 l
if
e-
th
re
at
en
in
g 
in
fe
ct
io
ns
.
23
U
se
 o
f 
va
nc
om
yc
in
, n
af
ci
lli
n,
 o
r 
m
et
ro
ni
d
az
ol
e 
w
as
 p
er
m
it
te
d
 f
or
 p
at
ie
nt
s 
w
it
h 
G
ra
m
-p
os
it
iv
e 
or
ga
ni
sm
s 
re
si
st
an
t 
to
 c
lin
d
am
yc
in
.
24
Pe
d
ia
tr
ic
 d
os
es
 w
er
e 
ad
ju
st
ed
 a
cc
or
d
in
g 
to
 w
ei
gh
t.
25
Pa
ti
en
ts
 e
nr
ol
le
d
 in
cl
ud
ed
 c
hi
ld
re
n 
3 
ye
ar
s 
of
 a
ge
 o
r 
ol
d
er
 a
nd
 a
d
u
lt
 p
at
ie
nt
s.
26
Si
gn
if
ic
an
tl
y 
d
if
fe
re
nt
  
( p
5
0.
02
) 
in
 f
av
or
 o
f 
ce
ft
ri
ax
on
e 
p
lu
s 
m
et
ro
ni
d
az
ol
e.
27
D
os
ag
e 
no
t 
re
p
or
te
d
.
28
A
ll 
p
at
ie
nt
s 
en
ro
lle
d
 w
er
e 
ch
ild
re
n 
be
tw
ee
n 
2 
an
d
 1
5 
ye
ar
s 
of
 a
ge
.
29
D
os
ag
e 
w
as
 m
od
if
ie
d
 a
cc
or
d
in
g 
to
 r
en
al
 f
un
ct
io
n.
30
Pa
ti
en
ts
 w
it
h 
su
p
er
fi
ci
al
 s
ur
gi
ca
l 
si
te
 i
nf
ec
ti
on
s 
w
er
e 
no
t 
ne
ce
ss
ar
ily
 c
on
si
d
er
ed
 f
ai
lu
re
s.
31
O
nl
y 
an
 i
nt
en
ti
on
-t
o-
tr
ea
t 
an
al
ys
is
 w
as
 r
ep
or
te
d
.
32
Fa
ilu
re
s 
in
cl
u
d
ed
 p
at
ie
nt
s 
w
ho
 r
ec
ei
ve
d
 a
d
di
ti
on
al
 a
nt
ib
io
ti
cs
 f
or
 a
ny
 r
ea
so
n,
 e
ve
n 
if
 u
nr
el
at
ed
 t
o 
th
e 
in
tr
a-
ab
d
om
in
al
 i
nf
ec
ti
on
.
33
M
or
ta
lit
y 
ra
te
 in
cl
ud
es
 p
at
ie
nt
s 
w
ho
 d
ie
d
 m
or
e 
th
an
 3
5 
d
ay
s 
af
te
r 
co
m
p
le
ti
on
 o
f 
th
er
ap
y.
34
Pe
rc
en
ta
ge
s 
of
 p
at
ie
nt
s 
w
it
h 
ap
pe
nd
ic
it
is
 w
er
e 
ba
se
d
 o
n 
al
l p
at
ie
nt
s 
en
ro
lle
d
 i
n 
th
e 
st
u
dy
.
35
A
ll 
p
at
ie
nt
s 
en
ro
lle
d
 w
er
e 
be
tw
ee
n 
1 
an
d
 1
6 
ye
ar
s 
of
 a
ge
.
36
Pa
ti
en
ts
 w
er
e 
en
ro
lle
d
 f
or
 n
os
oc
om
ia
l 
pn
eu
m
on
ia
, s
ep
si
s,
 o
r 
se
ve
re
 d
if
fu
se
 p
er
it
on
it
is
.
37
Su
cc
es
s 
ra
te
s 
re
fe
r 
on
ly
 t
o 
cl
in
ic
al
ly
 e
va
lu
ab
le
 p
at
ie
nt
s 
w
it
h 
p
er
it
on
it
is
.
38
T
he
 m
or
ta
lit
y 
ra
te
 w
as
 n
ot
 r
ep
or
te
d
 s
ep
ar
at
el
y 
fo
r 
pa
ti
en
ts
 w
it
h 
p
er
it
on
it
is
. T
he
 m
or
ta
lit
y 
ra
te
 d
u
e 
to
 in
fe
ct
io
n 
in
 a
ll 
en
ro
lle
d
 p
at
ie
nt
s 
w
as
 1
3%
 in
 p
at
ie
nt
s 
tr
ea
te
d
w
it
h 
im
ip
en
em
/
ci
la
st
at
in
 a
nd
 9
%
 i
n 
p
at
ie
nt
s 
tr
ea
te
d
 w
it
h 
im
ip
en
em
/
ci
la
st
at
in
 p
lu
s 
ne
ti
lm
ic
in
.
39
T
he
 m
ea
n 
A
P
A
C
H
E
 I
I 
sc
or
e 
fo
r 
pa
ti
en
ts
 w
it
h 
p
er
it
on
it
is
 w
as
 n
ot
 r
ep
or
te
d
. 
T
he
 m
ea
n 
A
P
A
C
H
E
 I
I 
sc
or
es
 f
or
 a
ll 
en
ro
lle
d
 p
at
ie
nt
s 
w
er
e 
9.
8 
fo
r 
pa
ti
en
ts
 t
re
at
ed
w
it
h 
im
ip
en
em
/
ci
la
st
at
in
 a
nd
 9
.6
 f
or
 p
at
ie
nt
s 
tr
ea
te
d
 w
it
h 
im
ip
en
em
/
ci
la
st
at
in
 p
lu
s 
ne
ti
lm
ic
in
.
40
Pa
ti
en
ts
 w
it
h 
pe
ri
to
ni
ti
s 
in
 t
he
 im
ip
en
em
/c
ila
st
at
in
 g
ro
u
p 
ha
d
 h
ig
he
r 
A
P
A
C
H
E
 I
I 
sc
or
es
.
41
A
ft
er
 3
 d
ay
s 
of
 t
re
at
m
en
t, 
or
al
 c
ip
ro
fl
ox
ac
in
 (
50
0–
75
0 
bi
d
) 
co
ul
d
 b
e 
su
bs
ti
tu
te
d
 f
or
 i
nt
ra
ve
no
us
 c
ip
ro
fl
ox
ac
in
.
42
G
en
ta
m
ic
in
 w
as
 d
is
co
nt
in
u
ed
 a
ft
er
 3
 d
ay
s 
in
 5
1%
 o
f 
pa
ti
en
ts
 w
ho
se
 o
rg
an
is
m
s 
w
er
e 
se
ns
it
iv
e 
to
 c
ef
ot
ax
im
e.
43
Si
gn
if
ic
an
tl
y 
d
if
fe
re
nt
 (
p
5
0.
02
) 
in
 f
av
or
 o
f 
ci
p
ro
fl
ox
ac
in
 p
lu
s 
m
et
ro
ni
d
az
ol
e.
44
N
et
ilm
ic
in
 c
ou
ld
 b
e 
ad
m
in
is
te
re
d
 in
tr
am
u
sc
u
la
rl
y 
or
 i
nt
ra
ve
no
us
ly
.
45
O
ra
l a
d
m
in
is
tr
at
io
n 
of
 m
et
ro
ni
da
zo
le
 w
as
 p
er
m
it
te
d
.
46
M
et
ro
ni
d
az
ol
e 
w
as
 n
ot
 g
iv
en
 t
o 
28
%
 o
f 
pa
ti
en
ts
 r
ec
ei
vi
ng
 o
nc
e 
d
ai
ly
 n
et
ilm
ic
in
 a
nd
 t
o 
32
%
 o
f 
p
at
ie
nt
s 
re
ce
iv
in
g 
th
ri
ce
 d
ai
ly
 n
et
ilm
ic
in
.
47
O
ne
 p
at
ie
nt
 i
n 
th
e 
cl
in
ic
al
ly
 e
va
lu
ab
le
 p
op
u
la
ti
on
 h
ad
 a
 s
of
t 
ti
ss
ue
 i
nf
ec
ti
on
.
48
O
ra
l t
in
id
az
ol
e 
(1
 g
 q
d
) 
co
u
ld
 b
e 
su
bs
ti
tu
te
d
 f
or
 in
tr
av
en
ou
s 
ti
ni
d
az
ol
e.
49
Pa
ti
en
ts
 e
nr
ol
le
d
 in
cl
ud
ed
 c
hi
ld
re
n 
12
 y
ea
rs
 o
f 
ag
e 
an
d
 o
ld
er
 a
nd
 a
d
u
lt
s.
50
Si
gn
if
ic
an
tl
y 
d
if
fe
re
nt
 (
p
5
0.
00
1)
 in
 f
av
or
 o
f 
pi
p
er
ac
ill
in
/
ta
zo
ba
ct
am
.
51
Si
gn
if
ic
an
tl
y 
d
if
fe
re
nt
 (
p
5
0.
02
) 
in
 f
av
or
 o
f 
p
ip
er
ac
ill
in
/t
az
ob
ac
ta
m
.
52
Pa
ti
en
ts
 w
er
e 
en
ro
lle
d
 f
or
 n
os
oc
om
ia
l 
pn
eu
m
on
ia
 o
r 
p
er
it
on
it
is
.
53
O
f 
th
e 
15
9 
cl
in
ic
al
ly
 e
va
lu
ab
le
 p
at
ie
nt
s 
w
it
h 
p
er
it
on
it
is
, 2
9 
d
id
 n
ot
 u
nd
er
go
 a
 s
ur
gi
ca
l 
pr
oc
ed
u
re
.
54
O
nl
y 
m
or
ta
lit
y 
at
tr
ib
u
ta
bl
e 
to
 in
fe
ct
io
n 
w
as
 r
ep
or
te
d
.
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55
Su
cc
es
s 
ra
te
s 
w
er
e 
ca
lc
ul
at
ed
 a
ft
er
 e
xc
lu
d
in
g 
p
at
ie
nt
s 
w
it
h 
in
co
m
p
le
te
 f
ol
lo
w
-u
p
 o
r 
in
d
et
er
m
in
at
e 
ou
tc
om
es
.
56
A
ft
er
 2
 d
ay
s,
 p
at
ie
nt
s 
co
u
ld
 b
e 
sw
it
ch
ed
 t
o 
bl
in
d
ed
 t
he
ra
py
 w
it
h 
or
al
 c
ip
ro
fl
ox
ac
in
 a
nd
 o
ra
l 
m
et
ro
ni
d
az
ol
e.
 D
os
ag
es
 n
ot
 r
ep
or
te
d
.
57
Si
gn
if
ic
an
tl
y 
d
if
fe
re
nt
 (
p
5
0.
04
7)
 i
n 
fa
vo
r 
of
 c
ip
ro
fl
ox
ac
in
 p
lu
s 
m
et
ro
ni
d
az
ol
e.
58
A
m
ik
ac
in
, 1
5 
m
g/
kg
/
d
ay
, c
ou
ld
 b
e 
ad
d
ed
 a
t t
he
 in
ve
st
ig
at
or
’s
 d
is
cr
et
io
n 
fo
r 
ad
d
it
io
na
l c
ov
er
ag
e 
of
 P
se
ud
om
on
as
.
59
T
w
el
ve
 p
at
ie
nt
s 
ra
nd
om
iz
ed
 to
 r
ec
ei
ve
 a
sp
ox
ic
ill
in
 a
nd
 1
3 
p
at
ie
nt
s 
ra
nd
om
iz
ed
 to
 r
ec
ei
ve
 p
ip
er
ac
ill
in
 w
er
e 
gi
ve
n 
an
 a
d
d
it
io
na
l a
nt
im
ic
ro
bi
al
, u
su
al
ly
 a
n 
am
in
og
ly
-
co
si
d
e.
60
A
ft
er
 th
e 
st
ar
t o
f t
he
ra
py
, p
at
ie
nt
s 
co
ul
d
 b
e 
sw
it
ch
ed
 to
 o
ra
l c
ip
ro
fl
ox
ac
in
 7
50
 m
g 
q1
2h
 p
lu
s 
or
al
 m
et
ro
ni
d
az
ol
e 
20
0 
m
g 
q1
2h
.
61
C
on
ta
in
s 
1 
g 
of
 a
m
ox
ac
ill
in
 a
nd
 2
00
 m
g 
of
 c
la
vu
la
ni
c 
ac
id
.
62
A
ft
er
 th
e 
st
ar
t o
f t
he
ra
py
, p
at
ie
nt
s 
co
ul
d
 b
e 
sw
it
ch
ed
 to
 o
ra
l a
m
ox
ac
ill
in
/c
la
vu
la
ni
c 
ac
id
 8
75
 m
g 
q8
h 
pl
u
s 
m
et
ro
ni
d
az
ol
e 
20
0 
m
g 
q1
2h
.
63
A
ft
er
 th
e 
st
ar
t o
f t
he
ra
py
, p
at
ie
nt
s 
co
ul
d
 b
e 
sw
it
ch
ed
 to
 o
ra
l t
ro
va
fl
ox
ac
in
, 2
00
 m
g 
qd
, a
t t
he
 in
ve
st
ig
at
or
’s
 d
is
cr
et
io
n.
64
A
ft
er
 th
e 
st
ar
t o
f t
he
ra
py
, p
at
ie
nt
s 
co
ul
d
 b
e 
sw
it
ch
ed
 to
 o
ra
l a
m
ox
ac
ill
in
/c
la
vu
la
ni
c 
ac
id
 5
0 
m
g 
q8
h.
65
A
ll 
p
at
ie
nt
s 
ha
d 
d
ia
gn
os
es
 c
on
si
st
en
t w
it
h 
ID
SA
 c
ri
te
ri
a,
 b
u
t p
at
ie
nt
s 
w
it
h 
ne
ga
ti
ve
 p
er
it
on
ea
l c
u
lt
u
re
s 
w
er
e 
co
ns
id
er
ed
 c
lin
ic
al
ly
 e
va
lu
ab
le
.
66
T
he
 s
ou
rc
e 
of
 th
e 
in
fe
ct
io
n 
w
as
 n
ot
 fu
lly
 e
xp
la
in
ed
 in
 p
at
ie
nt
s 
ha
vi
ng
 b
ac
te
re
m
ia
 a
ss
oc
ia
te
d
 w
it
h 
an
 a
p
pe
nd
ic
ea
l o
r 
co
lo
ni
c 
pe
rf
or
at
io
n.
67
D
os
ag
e 
of
 c
ef
m
et
az
ol
e 
co
u
ld
 b
e 
in
cr
ea
se
d
 to
 8
 g
 p
er
 d
ay
 a
t t
he
 in
ve
st
ig
at
or
’s
 d
is
cr
et
io
n.
68
D
os
ag
e 
of
 c
ef
ox
it
in
 c
ou
ld
 b
e 
in
cr
ea
se
d 
to
 1
2 
g 
p
er
 d
ay
 a
t t
he
 in
ve
st
ig
at
or
’s
 d
is
cr
et
io
n.
69
T
he
 n
um
be
rs
 o
f c
lin
ic
al
ly
 e
va
lu
ab
le
 p
at
ie
nt
s 
w
er
e 
no
t r
ep
or
te
d
 fo
r 
th
e 
tw
o 
st
u
dy
 g
ro
up
s.
70
T
he
 n
um
be
rs
 o
f s
uc
ce
ss
fu
lly
 tr
ea
te
d
 p
at
ie
nt
s 
w
er
e 
no
t r
ep
or
te
d 
fo
r 
th
e 
tw
o 
st
u
d
y 
gr
ou
ps
.
71
T
he
 a
ut
ho
rs
 s
ta
te
d
 th
at
 th
er
e 
w
er
e 
no
 s
ta
ti
st
ic
al
ly
 s
ig
ni
fi
ca
nt
 d
if
fe
re
nc
es
 in
 s
uc
ce
ss
 r
at
es
 c
om
pa
ri
ng
 c
ef
m
et
az
ol
e 
an
d
 c
ef
ox
it
in
.
72
Si
gn
if
ic
an
tl
y 
d
if
fe
re
nt
 ( p
5
0.
00
8)
 in
 fa
vo
r 
of
 c
ef
ot
ax
im
e 
p
lu
s 
m
et
ro
ni
d
az
ol
e.
73
A
t l
at
er
, f
ol
lo
w
-u
p,
 s
u
cc
es
s 
ra
te
s 
w
er
e 
98
%
 fo
r 
54
 p
at
ie
nt
s 
tr
ea
te
d
 w
it
h 
m
er
op
en
em
, a
nd
 9
7%
 fo
r 
64
 p
at
ie
nt
s 
tr
ea
te
d
 w
it
h 
ce
fo
ta
xi
m
e 
pl
u
s 
m
et
ro
ni
d
az
ol
e.
74
Si
gn
if
ic
an
tl
y 
d
if
fe
re
nt
 ( p
5
0.
00
8)
 in
 fa
vo
r 
of
 m
er
op
en
em
.
75
M
or
ta
lit
y 
ra
te
s 
w
er
e 
re
po
rt
ed
 a
t t
he
 e
nd
 o
f t
he
ra
py
 fo
r a
ll 
p
at
ie
nt
s 
en
ro
lle
d
 in
 th
e 
st
u
d
y.
 D
ur
in
g 
su
bs
eq
u
en
t f
ol
lo
w
-u
p
, m
or
ta
lit
y 
in
cr
ea
se
d
 to
 6
%
 fo
r p
at
ie
nt
s 
tr
ea
te
d
w
it
h 
m
er
op
en
em
 a
nd
 to
 1
1%
 fo
r 
p
at
ie
nt
s 
tr
ea
te
d
 w
it
h 
ce
fo
ta
xi
m
e 
p
lu
s 
m
et
ro
ni
d
az
ol
e.
76
Pa
ti
en
ts
 w
er
e 
en
ro
lle
d
 fo
r 
in
tr
a-
ab
d
om
in
al
 in
fe
ct
io
ns
 a
nd
 o
th
er
 in
d
ic
at
io
ns
.
77
T
he
se
 v
al
ue
s 
re
p
re
se
nt
 th
e 
nu
m
be
rs
 o
f c
lin
ic
al
ly
 e
va
lu
ab
le
 p
at
ie
nt
s 
w
ho
 h
ad
 in
tr
a-
ab
d
om
in
al
 in
fe
ct
io
ns
. S
om
e 
pa
ti
en
ts
 m
ay
 h
av
e 
ha
d 
ot
he
r 
in
fe
ct
io
ns
 a
s 
w
el
l.
78
Su
cc
es
s 
ra
te
s 
fo
r 
cl
in
ic
al
ly
 e
va
lu
ab
le
 p
at
ie
nt
s 
w
it
h 
in
tr
a-
ab
d
om
in
al
 in
fe
ct
io
ns
 w
er
e 
es
ti
m
at
ed
 f
ro
m
 d
at
a 
pr
ov
id
ed
 in
 t
he
 a
rt
ic
le
. S
u
cc
es
s 
ra
te
s 
in
cl
u
d
e 
pa
ti
en
ts
 r
e-
po
rt
ed
 a
s 
cu
re
d
 o
r 
im
p
ro
ve
d
.
79
Si
gn
if
ic
an
tl
y 
d
if
fe
re
nt
 ( p
5
0.
02
) i
n 
fa
vo
r 
of
 c
ef
ep
im
e 
p
lu
s 
m
et
ro
ni
d
az
ol
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tions. Recommendations regarding higher-
risk patients will be discussed in the subse-
quent section.
Summary of findings
Aminoglycosides. The combination of an
aminoglycoside and an antianaerobic agent
was considered the mainstay of antimicrobial
therapy for intra-abdominal infections until
newer agents were found to be equally effec-
tive. Thus, this combination was extensively
used as a comparator in many trials of newer
antimicrobials. The committee reviewed 27
studies, including three published prior to
1990, in which the combination of an amino-
glycoside plus an antianaerobic agent was com-
pared to other regimens [40–66]. One addi-
tional study compared the efficacy of two
different aminoglycosides in combination with
an antianaerobic agent [67]. There were also
three studies in which an aminoglycoside was
tested in combination with other agents having
extended spectrum gram-negative coverage
[68–70]. These latter studies will be considered
more fully in the subsequent discussion of ther-
apy for higher risk patients with intra-abdom-
inal infections.
A total of 1,786 clinically evaluable patients
were treated with aminoglycoside-based regi-
mens in the 28 studies reviewed. The amino-
glycosides tested included gentamicin, to-
bramycin, netilmicin, amikacin, and isepamicin.
Either clindamycin or metronidazole were
utilized as the antianaerobic agents in all
studies, and in one study [65] ornidazole was
also tested. This regimen was compared to a
variety of other single agents or combination
regimens, including an extended-spectrum
penicillin alone or combined with a beta-lac-
tamase inhibitor [41,42,49,56,60,61,65], a sec-
ond-generation cephalosporin with intrinsic
anaerobic coverage [40,53,59,66], a third- or
fourth-generation cephalosporin in combina-
tion with an antianaerobic agent or a beta-
lactamase inhibitor [43,44,46,50,52,55,58,65]
aztreonam plus clindamycin [51,57], a car-
bapenem alone [47,48,54,62-64], or the combi-
nation of a fluoroquinolone plus metronida-
zole [45]. In one study, the aminoglycosides,
isepamicin and amikacin were compared [67].
In six of these studies, antibiotics effective
against Enterococcus or other gram-positive
organisms were permitted or required along
with the aminoglycoside and the antianaero-
bic agent [48,50–52,60,65].
Many of these 28 studies involved patients
with relatively low–acuity infections. Nine stud-
ies enrolled patients with appendicitis only
[41,43,49,50,53,55,59,63,65]. Mortality among
aminoglycoside-treated patients was greater
than 5% in only four of these studies
[40,47,48,58]. Many of these studies were pub-
lished toward the beginning of the decade, and
tended to be of relatively lower quality than later
studies.
Success rates using aminoglycoside-based
regimens ranged from 70% to 100% in these
studies except for one trial in which only the re-
sults of an ITT analysis were presented [58]. The
overall success rate was 86% for all 1,786 clini-
cally evaluable patients who received amino-
glycosides. The individual and overall success
rates were comparable to those obtained with
other antimicrobial regimens used for treating
intra-abdominal infections. Most of the studies
demonstrated no significant differences in pa-
tient outcome between the aminoglycoside-
based and comparator regimens, but in five
studies the differences in success rates were sta-
tistically significant. Success rates were lower
with an aminoglycoside-based regimen com-
pared to a third-generation cephalosporin plus
an antianaerobe in two studies, compared to a
third-generation cephalosporin/beta-lactamase
inhibitor combination in one study, and com-
pared to carbapenem in one study [43,44,48,52].
In two of these studies, the higher failure rates
observed in aminoglycoside-treated patients
were due entirely to an increase in superficial
surgical site infections [43,52]. In contrast to
these studies, an earlier study found an amino-
glycoside-based regimen to be superior to ampi-
cillin/sulbactam for patients with complicated
appendicitis [41].
In analyzing the results of their trial compar-
ing imipenem/cilastatin with tobramycin plus
clindamycin, Solomkin et al. [48] suggested that
a delay in achieving therapeutic tobramycin
concentrations contributed to the higher failure
rate observed in patients who received the
aminoglycoside-based regimen. Among the
other studies that described lower success rates
with aminoglycoside-based therapy, one did
not report any monitoring of serum aminogly-
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coside concentrations [52], and the other two
did not comment on the time required to
achieve therapeutic aminoglycoside concentra-
tions [43,44]. Thus, if aminoglycoside-based
regimens are utilized, it would seem prudent to
direct attention toward prompt attainment of
therapeutic concentrations of these agents, per-
haps by using a once-daily dosing strategy.
Once-daily administration of aminoglyco-
sides is an alternative that simplifies the use of
these agents, and potentially avoids problems of
underdosing. In a large meta-analysis of patients
treated with aminoglycosides for any indication,
once-daily aminoglycoside dosing was associ-
ated with similar efficacy and possibly de-
creased toxicity compared to multiple daily dose
regimens [71]. Two prospective randomized
controlled trials have compared once-daily with
multiple daily dose regimens of netilmicin in pa-
tients with intra-abdominal infections [72,73].
Success rates were greater than 90% in the treat-
ment arms of both studies, and no significant
differences in therapeutic efficacy or toxicity
were detected. However, many of the evaluable
patients in these studies had relatively mild in-
fections, and it is uncertain if these results ap-
ply to a more severely ill population of patients
receiving aminoglycosides.
Based on these studies using aminoglycoside-
based regimens, the Committee continues to in-
clude the combination of an aminoglycoside
with an antianaerobic agent in the list of rec-
ommended agents for the treatment of intra-ab-
dominal infections. However, given the equiva-
lent performance of other regimens and the
nephrotoxicity and ototoxicity of aminoglyco-
sides, these drugs should not necessarily be con-
sidered first-line agents for therapy. They may
be of greater use for patients who have failed
therapy with other agents or for patients with
severe allergic reactions to other antimicrobials.
Penicillin/beta-lactamase inhibitor combinations.
In the previous guidelines [1], ticarcillin/clavu-
lanic acid was the only recommended agent in
this class for the treatment of patients with 
intra-abdominal infections. However, ampi-
cillin/sulbactam has been employed frequently
for this indication. The Committee identified at
least three prospective randomized controlled
trials that evaluated use of this agent, two of
which were published prior to 1990. In these
studies, ampicillin/sulbactam was compared
against gentamicin plus clindamycin [41,42] or
cefoxitin [74]. One study enrolled only patients
with complicated appendicitis [41]. Mortality
in all studies appeared to be low.
A total of 209 clinically evaluable patients re-
ceived ampicillin/sulbactam in these trials. The
reported success rates were 86–88% in the in-
dividual trials; among all 209 patients who re-
ceived ampicillin/sulbactam, the success rate
was 87%. In one trial, limited to patients with
complicated appendicitis [41], the failure rate
was significantly higher with ampicillin/sul-
bactam than with gentamicin and clindamycin.
However, one-half of these failures were due
to superficial surgical site infections. In addi-
tion, there was an imbalance in randomization,
such that fewer patients with gangrenous ap-
pendicitis and more patients with perforated
appendicitis received ampicillin/sulbactam
than received gentamicin plus clindamycin. In
the other two studies, there were no significant
differences in therapeutic efficacy comparing
ampicillin/sulbactam to the other agents. Based
on these limited data and the relatively wide-
spread clinical use of this agent, the Committee
has included ampicillin/sulbactam in the list of
acceptable single agents for the treatment of pa-
tients with intra-abdominal infections.
The use of ticarcillin/clavulanic acid for the
treatment of intra-abdominal infections was
described further in three trials published be-
tween 1990 and 2000 [49,60,75]. This agent was
compared to gentamicin-containing regimens
in two studies [49,60] and to imipenem/cila-
statin in one [75]. Two of these trials enrolled
only patients with complicated appendicitis
[49,75], and mortality in all studies appeared to
be low. Overall, these trials included 324 clini-
cally evaluable patients treated with ticar-
cillin/clavulanic acid. Success rates in these 
trials ranged from 86% to 97%. The overall suc-
cess rate among all patients treated with ticar-
cillin/clavulanic acid was 88%. There were no
statistically significant differences in outcome
in any of the studies. The Committee continues
to recommend ticarcillin/clavulanic acid for
antimicrobial therapy of intra-abdominal in-
fections.
The use of piperacillin/tazobactam for treat-
ment of patients with intra-abdominal infections
was examined in eight trials published over the
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past decade [56,61,76-81], and the use of
piperacillin alone was evaluated in another
three [65,82,83]. Comparator regimens included
an aminoglycoside plus an antianaerobic agent
[56,61,65], imipenem/cilastatin [76–78], cefurox-
ime plus metronidazole [79,82], a third-genera-
tion cephalosporin plus an antianaerobic agent
[65,81], ciprofloxacin plus metronidazole [80],
and another extended-range penicillin, aspoxi-
cillin [83]. Only one of these trials [65] was re-
stricted to patients with appendicitis. Mortality
was greater than 5% in two trials [81,82].
In these studies, 571 clinically evaluable pa-
tients were treated with piperacillin/tazobac-
tam, and an additional 141 patients were
treated with piperacillin alone. Success rates
with piperacillin/tazobactam or piperacillin
alone ranged from 63% to 98% in individual tri-
als, and the overall success rate for all clinically
evaluable patients was 85%. Success rates were
equivalent to the comparators in all trials ex-
cept two. In one trial, piperacillin/tazobactam
appeared to be superior to imipenem/cilastatin
[76]. However, patients treated with the car-
bapenem had an unexpectedly low success rate
compared to that observed in other trials with
this agent [84]. In another study, treatment with
piperacillin/tazobactam appeared to be less ef-
ficacious than treatment with ciprofloxacin
plus metronidazole when the analysis was
based on clinically evaluable patients, but this
difference was not statistically significant in a
modified ITT analysis [80]. Based on these data,
the Committee has included piperacillin/
tazobactam in the list of recommended regi-
mens for the treatment of patients with intra-
abdominal infections. The use of piperacillin
alone also appears to be acceptable for the treat-
ment of these patients, but the use of
piperacillin alone seems to have been greatly
curtailed since piperacillin/tazobactam be-
came available. The Committee therefore has
made no separate recommendation with re-
gard to the use of piperacillin alone.
The extended spectrum penicillin/beta lacta-
mase regimens described here, particularly
ampicillin/sulbactam and piperacillin/tazobac-
tam, cover most isolates of Enterococcus recov-
ered from patients with community-acquired
intra-abdominal infections. In three studies
evaluating ampicillin/sulbactam [41,42,74] and
six studies evaluating piperacillin/tazobactam
or piperacillin alone [56,61,79–82], the com-
parator regimen would not have had similar
coverage. The trial of Röhrborn et al. [81] was
designed specifically to study the need for en-
terococcal coverage in patients treated for com-
munity-acquired intra-abdominal infections.
None of these trials demonstrated any advan-
tage to the extended spectrum penicillin/beta-
lactamase regimen. Thus, these data suggest
that routine coverage of Enterococcus is not nec-
essary for most patients with community-ac-
quired intra-abdominal infections.
In two studies, oral amoxicillin/clavulanic
acid was used to complete a course of intra-
venous amoxacillin/clavulanic acid or
imipenem/cilastatin [85,86]. Utilization of the
oral agent was at the investigator’s discretion,
however, and not according to a specific pro-
tocol. A prospective trial of an obligatory in-
travenous regimen compared to one permitting
conversion to oral amoxicillin/clavulanic acid
has not been conducted. Based on the limited
evidence from these two trials, the use of oral
amoxicillin/clavulanic acid to complete a
course of intravenous antimicrobials appears to
be an acceptable option for selected patients
with intra-abdominal infections who are able
to tolerate an oral diet.
Cephalosporins. In the previous guidelines,
Bohnen et al. [1] recommended second-genera-
tion cephalosporins with anaerobic coverage,
specifically cefoxitin, cefotetan, and cefmetazole,
as acceptable monotherapy for the treatment of
patients with intra-abdominal infections of mild
to moderate severity. The use of these agents has
been examined in at least eight prospective ran-
domized controlled trials, four of which have
been published since 1990 [40,53,59,74,87–90].
Two of these trials [53,59] were restricted to pa-
tients with appendicitis. In only one study was
mortality greater than 5% [40].
Cefoxitin was compared to an aminoglyco-
side plus clindamycin [40,53], ampicillin/sul-
bactam [74], cefotetan [87], cefmetazole [89], or
imipenem/cilastatin [90] in six studies en-
rolling an estimated 337 clinically evaluable pa-
tients. Reported success rates ranged from 78%
to 97% in these trials. The overall success rate
among all cefoxitin-treated patients was 85%.
Cefotetan was compared to amikacin plus clin-
damycin [59], cefoxitin [87], or moxalactam [88]
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in 244 clinically evaluable patients. Success
rates in the cefotetan-treated patients ranged
from 90% to 98% in these three trials. The suc-
cess rate among all patients treated with ce-
fotetan was 95%. Among clinically evaluable
patients who received either cefoxitin or ce-
fotetan, the overall success rate was 89%. There
were no statistically significant differences in
outcome in any of the trials which utilized ce-
foxitin or cefotetan.
The Committee could identify only a single
prospective randomized controlled trial that
examined the use of cefmetazole for the treat-
ment of patients with intra-abdominal infec-
tions [89]. This small study enrolled 52 patients
treated with cefmetazole and 27 treated with
cefoxitin. An overall success rate of 92% was
described, but the success rates using each
agent were not described unambiguously. The
authors stated that there were no statistically
significant differences in clinical outcome com-
paring cefmetazole to cefoxitin.
Based on these data, the Committee continues
to recommend cefoxitin and cefotetan as ac-
ceptable agents for the empiric treatment of pa-
tients with intra-abdominal infections. Al-
though the spectrum of activity of cefmetazole
is similar to cefoxitin and cefotetan, the Com-
mittee does not believe that there is adequate ev-
idence to make a specific recommendation with
respect to this agent, particularly since it has not
been widely used for treating patients with in-
tra-abdominal infections following its initial
evaluation.
The efficacy of another second-generation
cephalosporin, cefuroxime, in combination
with metronidazole, was compared to that of
piperacillin/tazobactam [79], piperacillin alone
[82], or imipenem/cilastatin [91] in three clini-
cal trials, including 281 clinically evaluable pa-
tients. None of these studies was restricted to
patients with appendicitis, and none had a mor-
tality rate of greater than 5%. Cefuroxime plus
metronidazole was equivalent to the compara-
tor in each study, with success rates ranging
from 64% to 91% in individual studies. The over-
all success rate was 87% for all clinically evalu-
able patients treated with this regimen. Based
on these data, the combination of cefuroxime
plus metronidazole has been added to the rec-
ommended list of regimens for the treatment of
patients with intra-abdominal infections.
Bohnen et al. [1] included combinations of a
third-generation cephalosporin (cefotaxime,
ceftizoxime, ceftazidime, or ceftriaxone) with
an antianaerobic agent in their list of recom-
mended regimens for the treatment of patients
with intra-abdominal infections. Since 1990,
additional trials of cefotaxime [50,81,92–94],
ceftazidime [43,46], and ceftriaxone [52,65,81],
have been published. The fourth-generation
cephalosporin, cefepime, was also evaluated in
two published trials [55,95]. Metronidazole
was the antianaerobic agent used along with
the cephalosporin in most of these trials
[43,52,55,81,92–95], although clindamycin was
used in two trials [46,50] and ornidazole in one
other [65]. The comparator regimens included
an aminoglycoside plus an antianaerobic agent
[43,46,50,52,55,65], an extended spectrum peni-
cillin with or without a beta-lactamase inhibitor
or metronidazole [65,81], or a carbapenem [92–
95]. Four of these trials were restricted to pa-
tients with appendicitis [43,50,56,65]. Mortality
was greater than 5% in three trials, all of them
relatively recent [81,93,94].
In these eleven trials, 642 evaluable patients re-
ceived the combination of a third- or fourth-
generation cephalosporin with an antianaero-
bic agent. Overall success rates using the
cephalosporin-based regimens ranged from 75%
to 100%, with the rate being 92% for all patients
treated with this regimen. In five of these trials,
success rates with the cephalosporin-based reg-
imens differed significantly from those of the
comparators. In two of these trials, as indicated
previously, outcome was significantly better
with a cephalosporin-based regimen compared
to an aminoglycoside-based regimen [43,52]. In
two other trials, the cephalosporin-based regi-
men was significantly favored over a car-
bapenem [92,95], but the opposite was found in
one additional trial [93]. In the largest of these
trials [95], the combination of cefepime and
metronidazole appeared to be superior to
imipenem/cilastatin in an unadjusted analysis.
However, the authors noted that there was an
imbalance in randomization; patients who re-
ceived imipenem/cilastatin had higher mean
APACHE II scores than patients who received
cefepime plus metronidazole. After using a mul-
tivariate analysis to adjust for differences in clin-
ical risk factors, the statistical advantage in favor
of cefepime plus metronidazole was lost. In ad-
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dition, no statistically significant differences
were found in an ITT analysis.
Based on the aggregate data, the Committee
continues to include the combination of a third-
or fourth-generation cephalosporin with an an-
tianaerobic agent in the list of recommended
agents for the treatment of patients with intra-
abdominal infections. The previous guidelines of
Bohnen et al. [1] included cefotaxime, cef-
tazidime, ceftriaxone, and ceftizoxime as accept-
able third-generation cephalosporins, to which
the fourth-generation cephalosporin, cefepime,
can be added. It should be noted, however, that
the data in support of some of these individual
agents are limited, and no new publications
supporting the use of ceftizoxime were identi-
fied. Thus, it is uncertain if these agents are ac-
tually all of equivalent therapeutic efficacy.
Monobactams. Aztreonam plus clindamycin
was listed previously as an acceptable regimen
for the treatment of patients with intra-abdom-
inal infections [1]. Three additional prospective
trials, including 177 clinically evaluable patients
treated with this regimen, have been published
since 1990 [51,57,96]. Aztreonam plus clin-
damycin was compared to an aminoglycoside
plus clindamycin in two studies [51,57] and to
imipenem/cilastatin in one [96]. None of these
trials was restricted to patients with appendici-
tis, and none had a mortality rate of greater than
5%. The success rates with aztreonam plus clin-
damycin ranged from 71% to 100% in the indi-
vidual trials. The overall success rate was 84%
among all patients treated with this regimen.
There were no statistically significant differ-
ences between aztreonam plus clindamycin and
the comparators in any of the trials. The Com-
mittee continues to recommend this regimen for
the treatment of patients with intra-abdominal
infections.
Carbapenems. Imipenem/cilastatin was also in-
cluded previously in the list of recommended
agents for the treatment of intra-abdominal in-
fections [1]. In studies published between 1990
and 2000, both imipenem/cilastatin and another
carbapenem, meropenem, were evaluated ex-
tensively as single agents for the treatment of
patients with intra-abdominal infections. In 13
trials, imipenem/cilastatin was compared to
agents in other antimicrobial classes [47,48,
54,75–78,86,90,91,95–97], and in six studies
meropenem was compared to other therapeutic
agents [62–64,92–94]. In five additional studies,
imipenem/cilastatin and meropenem were
compared with each other [98–102], and in one
study, imipenem/cilastatin was compared to
another carbapenem, biapenem [103].
In all, imipenem/cilastatin was used in 1,496
clinically evaluable patients, compared against
an aminoglycoside plus an antianaerobic agent
[47,48,54], ticarcillin/clavulanic acid [75],
piperacillin/tazobactam [76–78], cefoxitin [90],
cefuroxime [91] or cefepime [95] plus metro-
nidazole, aztreonam plus clindamycin [96],
ciprofloxacin plus metronidazole [97], ala-
trofloxacin [86], meropenem [98–102], or bia-
penem [103]. Completion of therapy with oral
amoxacillin/clavulanic acid was permitted in
one study [86]. Only one of these studies [75]
was limited to patients with an appendiceal
source of infection. Mortality rates greater than
5% were observed in six of the studies compar-
ing imipenem/cilastatin against other agents
[47,48,76,91,95,97] and in one study comparing
imipenem/cilastatin with meropenem [102].
Success rates using imipenem/cilastatin
ranged from 69% to 100% in the individual tri-
als. The success rate among all 1,496 clinically
evaluable patients who received imipenem/
cilastatin was 87%. In three studies [48,76,95],
discussed previously, statistically significant
differences in success rates were observed be-
tween imipenem/cilastatin and the other
agents. One of these trials favored imipenem/
cilastatin [48] and two favored the compara-
tors [76,95]. There were no statistically sig-
nificant differences in outcome in any of the
studies comparing imipenem/cilastatin and
meropenem.
Meropenem was tested in 768 clinically evalu-
able patients, and it was compared against to-
bramycin plus clindamycin [62–64], cefotaxime
plus metronidazole [92–94], and imipenem/
cilastatin [98–102]. One of these studies [63] in-
cluded only patients with appendicitis. Mortal-
ity rates were greater than 5% in three studies
[93,94,102]. In individual trials, the clinical suc-
cess rates using meropenem ranged from 91%
to 100%. The success rate in all patients treated
with meropenem was 95%. One trial comparing
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meropenem to cefotaxime plus metronidazole
found the success rate to be significantly higher
with meropenem [93], but the opposite was
found in another trial [92].
A meta-analysis by Chang and Wilson [84]
further supported the use of carbapenems for
the treatment of patients with intra-abdominal
infections. This study summarized the results
of ten trials comparing imipenem/cilastatin or
meropenem against non-carbapenem com-
parators. Overall, there were no significant dif-
ferences in success rates comparing the car-
bapenems against other regimens. There were
also no significant differences in outcome in
separate assessments of imipenem/cilastatin
and meropenem against their respective com-
parators. Based on this large body of evidence,
the Committee continues to recommend
imipenem/cilastatin for the treatment of pa-
tients with intra-abdominal infections, and has
added meropenem to the list of acceptable
agents.
As with the extended spectrum penicillin/
beta lactamase inhibitor combinations, both
imipenem/cilastatin and meropenem cover
routine isolates of Enterococcus faecalis. In many
of the studies cited above, the non-carbapenem
comparator would not have been expected 
to provide reliable enterococcal coverage
[47,48,54,62–64,90–97]. However, there was no
evidence that the enterococcal coverage pro-
vided by the carbapenems improved clinical
outcome in any of these trials. These data, along
with the data from studies of extended spec-
trum penicillin/beta-lactamase inhibitor com-
binations, support the conclusion that routine
coverage of Enterococcus is unnecessary for
most patients with community-acquired intra-
abdominal infections.
Recently, a newer carbapenem, ertapenem,
was tested against piperacillin/tazobactam in a
large prospective randomized controlled trial
reported at the Annual Meeting of the SIS in
2001 [104]. Overall, 203 clinically evaluable pa-
tients were treated with ertapenem, of whom
61% had perforated appendicitis. The mortality
rate in this study was 6%. The success rate in pa-
tients treated with ertapenem was 87%, which
was equivalent to the 81% success rate observed
in patients treated with piperacillin/tazobac-
tam. Based on the data from this large trial, the
Committee has added ertapenem to the list of
acceptable therapeutic agents for the treatment
of patients with intra-abdominal infections.
However, clinical experience with this agent is
limited at present, so its overall usefulness for
this indication has yet to be defined fully.
Fluoroquinolones. The role of fluoroquinolones
in treating patients with intra-abdominal infec-
tions was investigated increasingly over the
past decade. Four trials compared the combi-
nation of ciprofloxacin plus metronidazole with
amoxacillin/clavulanic acid plus metronida-
zole [85]; piperacillin/tazobactam [80]; cefo-
taxime, gentamicin, and metronidazole [69]; or
imipenem/cilastatin [97]. None of these studies
was restricted to patients with appendicitis.
Mortality rates over 5% were observed in three
of the four trials [69,80,97].
These four studies included 429 clinically
evaluable patients who received ciprofloxacin
plus metronidazole. Success rates using this
regimen ranged from 74% to 97%, and the suc-
cess rate among all clinically evaluable patients
was 82%. In two trials, there was a statistically
significant difference in success rates favoring
the ciprofloxacin plus metronidazole regimen
[69,80], although this advantage was not ob-
served in an ITT analysis performed as part of
one trial [80].
In a carefully designed study, Solomkin et 
al. [97] examined the efficacy of oral cipro-
floxacin and metronidazole in patients with in-
tra-abdominal infections. In this study, there
were two separate arms that involved treat-
ment with ciprofloxacin plus metronidazole. In
one arm, patients received only intravenous
ciprofloxacin and metronidazole, whereas in
the other, patients could receive blinded oral
therapy with the same agents after 3 days of in-
travenous therapy. Approximately 47% of the
patients in this trial were switched to oral med-
ications or placebos. Success rates were similar
among patients who received only intravenous
therapy and patients who were allowed to re-
ceive oral therapy.
Overall, the Committee believes that the ev-
idence justifies inclusion of the regimen of
ciprofloxacin plus metronidazole in the list of
recommended agents for the treatment of in-
tra-abdominal infections. There is also reason-
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able evidence that oral ciprofloxacin and
metronidazole can be used to complete an ini-
tial intravenous course of these agents for pa-
tients able to tolerate oral medications.
The role of other fluoroquinolones for the
treatment of intra-abdominal infections re-
mains to be determined. There is particular in-
terest in newer agents that are active against
anaerobic as well as aerobic gram-negative or-
ganisms, and thus could be used as single
agents for these infections. In one large study,
a regimen using intravenous alatrofloxacin fol-
lowed by oral trovafloxacin was found compa-
rable to a regimen of imipenem/cilastatin fol-
lowed by oral amoxicillin/clavulanic acid [86].
However, because of its hepatic toxicity, use of
alatrofloxacin and trovafloxacin was subse-
quently curtailed sharply, and this regimen
cannot be recommended at present. Additional
fluoroquinolones, such as moxifloxacin and
others still in clinical development, are cur-
rently being tested as monotherapy for patients
with intra-abdominal infections. Such agents
may provide additional therapeutic alterna-
tives for these patients in the future.
Antianaerobic agents. The previous guidelines
recommended clindamycin and metronidazole
as acceptable antianaerobic agents in combina-
tion regimens for the treatment of patients with
intra-abdominal infections. These guidelines
did not recommend the use of chlorampheni-
col because of its risk of side effects [1]. The
Committee uncovered very little recent data
with which to evaluate further these recom-
mendations.
In several studies, a trend toward increasing
in vitro resistance of B. fragilis and other anaer-
obes to several antianaerobic agents was ob-
served. However, this did not appear to be oc-
curring with metronidazole [105–107]. This led
some authors to question the use of antimicro-
bials such as cefoxitin and clindamycin for 
patients with intra-abdominal infections [107].
Although an occasional clinical failure in
prospective trials has been attributed to resis-
tant anaerobic bacteria, the overwhelming 
majority of prospective trials provide little in-
dication that success rates are influenced sig-
nificantly by the antianaerobic component of
the regimen, as long as anaerobic coverage is
present. Thus, the clinical relevance of the
changing resistance patterns of anaerobic or-
ganisms remains uncertain.
A few reports published between 1990 and
2000 evaluated the efficacy of the antianaero-
bic agents used to treat patients with intra-ab-
dominal infections. One small prospective
study compared 75 pediatric patients who re-
ceived a regimen of ampicillin/sulbactam and
gentamicin against 39 similar patients who re-
ceived a regimen of ampicillin, gentamicin and
clindamycin [108]. Success rates for both study
groups were 97%, suggesting that ampi-
cillin/sulbactam had adequate anaerobic effi-
cacy. Another prospective trial randomized pa-
tients with perforated appendicitis to receive
clindamycin, 900 mg given every 8 h or clin-
damycin, 600 mg given every 6 h; all patients
also received gentamicin to cover aerobic/fac-
ultative anaerobic gram-negative organisms
[109]. Success rates were 93% and 91% in 80 and
46 clinically evaluable patients, respectively. In
some studies, a lower dose of clindamycin, 600
mg given every 8 h, has been used. Rovers et
al. [110] compared patient outcomes in three se-
ries that used this dosing regimen with out-
comes in three other series that used a higher
dose of 900 mg q8h. These authors concluded
that the lower dose of clindamycin was less ef-
ficacious for the treatment of patients with in-
tra-abdominal infections. However, since none
of the studies included in the analysis by these
authors directly compared these two regimens,
this conclusion seems questionable.
Overall, the Committee does not believe that
the available data justify any change in the pre-
vious recommendations regarding antianaero-
bic agents. Thus, clindamycin or metronidazole
continue to be recommended as acceptable an-
tianaerobic components of combination regi-
mens used for the treatment of patients with
intra-abdominal infections.
Selection of antimicrobial agents. The recom-
mended antimicrobial agents for the treatment
of patients with intra-abdominal infections are
listed in Table 12. As discussed previously, the
Committee did not designate preferred or first-
line regimens, because the available evidence
did not prove that any specific regimen was su-
perior. Thus, for the treatment of most patients,
particularly those with mild-to-moderate com-
munity-acquired infections, selection of spe-
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cific antimicrobials must be based on criteria
other than clinical efficacy.
One property that could potentially guide se-
lection of an initial empiric regimen is the ac-
tivity of the antimicrobial agents against the
common bacterial organisms that cause intra-
abdominal infections. In actuality, all the rec-
ommended regimens are active against the typ-
ical aerobic and anaerobic pathogens observed
in patients with community-acquired infections.
The various antimicrobial agents differ with re-
spect to their coverage of Enterococcus and their
breadth of gram-negative coverage.
As discussed previously, there is little indica-
tion that routine enterococcal coverage is neces-
sary for most patients with community-acquired
intra-abdominal infections, therefore this should
not be a consideration. With regard to activity
against gram-negative organisms, some agents
such as second-generation cephalosporins or
ampicillin/sulbactam provide less coverage of
organisms such as Enterobacter and Pseudomonas
than do broader-spectrum agents in their
classes. Nonetheless, these antimicrobials have
generally performed as well as others in clinical
trials. Thus, the expanded gram-negative spec-
trum of many recommended antimicrobial
agents is not necessarily advantageous for pa-
tients with community-acquired intra-abdomi-
nal infections, who are at relatively low risk for
failure. In fact, since one of the guiding princi-
ples of antimicrobial therapy is to use an agent
with a narrower spectrum of activity when pos-
sible, it might even be preferable to use an
agent such as cefoxitin, cefotetan, ampicillin/
sulbactam, or ticarcillin/clavulanate for the ini-
tial empiric treatment of lower-risk patients 
with intra-abdominal infections. However, this
would not apply to patients likely to harbor
more resistant organisms, such as those already
in health care institutions or those who have re-
cently been treated with antimicrobial agents.
Another relevant consideration to the selec-
tion of specific antimicrobials for the treatment
of intra-abdominal infections is the toxicity of
different agents. Because of their narrow ther-
apeutic ranges and associated problems of oto-
toxicity and nephrotoxicity, aminoglycosides
are generally considered higher-risk agents.
Fear of toxicity may actually lead to under-
dosing of these agents, and thereby result in
therapeutic failure [48]. It would seem reason-
able to use these agents primarily for patients
with allergies to other antimicrobial agents or
when necessary to treat resistant organisms.
Cost considerations could play a role in the
selection of the initial empiric antimicrobial
therapy. However, determining the actual costs
of different regimens is problematic. The ac-
quisition costs of different antimicrobial agents
may be quite specific to a particular institution,
and differ substantially from national averages.
Costs of administration may add appreciably
to acquisition costs, but are difficult to estimate.
These may differ substantially for different reg-
imens according to how many antimicrobial
doses must be given. In addition, the relatively
low acquisition costs of certain agents, such as
aminoglycosides, may be offset by costs in-
curred with laboratory monitoring. Finally, the
use of oral antimicrobials might allow for out-
patient therapy, and thereby substantially de-
crease overall costs of treatment, notwith-
standing the expense of the antimicrobial
agents themselves.
An additional issue related to the use of an-
timicrobials for intra-abdominal infections is
whether or not to alter the initial empiric regi-
men according to the results of intraoperative
cultures. There is substantial controversy re-
garding the usefulness of intraoperative cul-
tures for most patients with intra-abdominal
infections, particularly those with community-
acquired infections. Several authors believe
that the routine use of such cultures is unwar-
TABLE 12. RECOMMENDED ANTIMICROBIAL REGIMENS
FOR INTRA-ABDOMINAL INFECTIONS
Single agents
Ampicillin/sulbactam
Cefotetan
Cefoxitin
Ertapenem
Imipenem/cilastatin
Meropenem
Piperacillin/tazobactam
Ticarcillin/clavulanic acid
Combination regimens
Aminoglycoside (amikacin, gentamicin, netilmicin,
tobramycin,) plus antianaerobe (clindamycin or
metronidazole)
Aztreonam plus clindamycin
Cefuroxime plus metronidazole
Ciprofloxacin plus metronidazole
Third/fourth-generation cephalosporin (cefepime, 
cefotaxime, ceftazidime, ceftizoxime, ceftriaxone)
plus antianaerobe
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ranted [111,112], while others still advocate
their use [90]. If peritoneal cultures are ob-
tained, however, it is common for the final re-
sults to reveal one or more organisms resistant
to the initial empiric antimicrobial regimen.
The consensus of the Committee is that if the
patient is showing an adequate clinical re-
sponse, there is little justification for changing
antimicrobial agents on the basis of culture re-
sults alone. Although this approach might be
considered in a patient who is not showing
signs of clinical improvement, there is also a
real possibility that such a patient has either a
persistent intra-abdominal infection requiring
further efforts at source control, or a nosoco-
mial infection outside the abdomen requiring
different types of antimicrobials altogether.
Under either of these circumstances, alteration
of the antimicrobial regimen based on the in-
traoperative culture results may not be suc-
cessful in treating the patient. The guidelines
developed regarding the use of antimicrobial
regimens for the treatment of patients with in-
tra-abdominal infections are listed in Table 13.
ANTIMICROBIAL THERAPY FOR THE
HIGHER-RISK PATIENT
Up to now, the guidelines have focused pri-
marily on antimicrobial therapy for lower risk
patients with common community-acquired 
intra-abdominal infections. Most of these pa-
tients are expected to make an uncomplicated
recovery following a primary source control
procedure and appropriate antimicrobial treat-
ment. However, there are some patients with
intra-abdominal infections for whom an un-
complicated postoperative course seems less
likely. This impression may be due to the over-
whelming nature of the infection itself, the pa-
tient’s severely limited physiological reserves,
or the failure of previous attempts at therapy.
TABLE 13. GUIDELINES FOR ANTIMICROBIAL REGIMENS FOR INTRA-ABDOMINAL INFECTIONS
1. Antimicrobial regimens for intra-abdominal infections should cover common aerobic and anaerobic enteric
flora. The following antimicrobials or combinations of antimicrobials are effective for the treatment of intra-
abdominal infections. No regimen has been demonstrated to be superior to another (Level 1).
Single agents:
Ampicillin/sulbactam
Cefotetan
Cefoxitin
Ertapenem
Imipenem/cilastatin
Meropenem
Piperacillin/tazobactam
Ticarcillin/clavulanic acid
Combination regimens:
Aminoglycoside (amikacin, gentamicin, netilmicin, tobramycin) plus antianaerobe (clindamycin or 
metronidazole)
Aztreonam plus clindamycin
Cefuroxime plus metronidazole
Ciprofloxacin plus metronidazole
Third/fourth-generation cephalosporin (cefepime, cefotaxime, ceftazidime, ceftizoxime, ceftriaxone) plus 
antianaerobe
2. For patients with mild-to-moderate community-acquired infections, agents having a narrower spectrum of
activity, such as antianaerobic cephalosporins, ampicillin-sulbactam, or ticarcillin-clavulanic acid are preferable to
more costly agents having broader coverage of gram-negative organisms and/or greater risk of toxicity (Level 3).
3. Completion of the antimicrobial course with oral forms of ciprofloxacin plus metronidazole (Level 2) or with
oral amoxacillin/clavulanic acid (Level 3) is acceptable in patients able to tolerate an oral diet.
4. Once-daily administration of aminoglycosides is the preferred dosing regimen for patients receiving these
agents for intra-abdominal infections. Careful attention should be paid to prompt attainment of therapeutic
antibiotic concentrations when aminoglycosides are used (Level 2).
5. Regimens providing enterococcal coverage are not routinely necessary in the treatment of most patients with
intra-abdominal infections (Level 2).
6. The routine use of intra-operative cultures is controversial. However, altering the antimicrobial regimen on the
basis of culture results does not improve outcome in patients having a satisfactory clinical response (Level 3).
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The selection of appropriate antimicrobial
therapy for higher-risk patients would be fa-
cilitated greatly by the identification of objec-
tive criteria for recognizing such patients. Sev-
eral analyses, in fact, have identified specific
risk factors that predict mortality in patients
with intra-abdominal infections. However,
many of these risk factors are the same as those
that predict perioperative mortality in any pa-
tient undergoing a surgical procedure, whether
or not an intra-abdominal infection is present.
Such risk factors relate primarily to patients’
underlying comorbidities, such as preexisting
cardiac disease or other medical problems.
These risk factors are probably of little rele-
vance in selecting specific antimicrobial regi-
mens to be used in the treatment of higher risk
patients with intra-abdominal infection. How-
ever, risk factors for treatment failure rather
than postoperative mortality, particularly those
that pertain to the pathogenic organisms in-
volved in the infection, might be more germane
to the selection of antimicrobial therapy for
higher risk patients. Unfortunately, relatively
few analyses have focused on the infection-re-
lated parameters that predict treatment failure.
Even if patients at higher risk for treatment
failure can be identified, the development of
specific recommendations is difficult because
relatively little Class I evidence pertains to
these higher-risk patients. As discussed previ-
ously, prospective randomized controlled tri-
als comparing different antimicrobials primar-
ily enrolled patients with community-acquired
intra-abdominal infections, such as perforated
appendicitis, who were likely at lower risk for
treatment failure and death. Many trials specif-
ically excluded higher risk patients.
To characterize further the studies compris-
ing the database, the Committee examined
mortality rates as crude indicators of the in-
clusion of higher-risk patients in the trials. No-
tably, three-quarters of the trials reported a
mortality of 5% or less, with a number report-
ing no mortality at all. This contrasts with mor-
tality rates ranging from 17% to 32% in several
series evaluating risk factors for treatment fail-
ure and death in patients with intra-abdominal
infections [113–118], and a mortality rate of 6%
in an epidemiological survey that was broadly
representative of patients with intra-abdominal
infections and included substantial numbers of
patients with complicated appendicitis [119].
The lower mortality rates found in clinical tri-
als compared to broader surveys of patients
with intra-abdominal infections support the
conclusion that most patients enrolled in clini-
cal trials were at relatively low risk for thera-
peutic failure, and that relatively few higher-
risk patients were enrolled in most of these
studies.
Therefore, the Committee believes it is inap-
propriate to apply the results of most clinical
trials to higher-risk patients. There were a few
clinical trials that specifically focused on
higher-risk patients, and these trials did pro-
vide some Class I evidence suitable for devel-
oping recommendations. However, in the end,
many of these recommendations for higher-
risk patients had to be based primarily on ex-
pert opinion.
Summary of findings
Identification of risk factors. For patients with
intra-abdominal infections, treatment failure
and death are likely related both to the sever-
ity of the infectious process as well as to the pa-
tient’s intrinsic physiological capacity to re-
spond to that infection. In a number of studies
that utilized multivariate analyses to identify
risk factors for treatment failure or death
[95,113–117], this latter capacity proved to be
of paramount importance in determining the
likelihood of an adverse outcome. The inde-
pendent risk factors identified in these studies
included higher APACHE II scores, advanced
age, malnutrition, hypoalbuminemia, hypo-
cholesterolemia, the presence of medical con-
ditions such as cardiovascular disease, renal
disease, and malignancy, and the use of corti-
costeroid medications (Table 14). Advanced
age and significant hypoalbuminemia were
identified as risk factors in more than one
study, but a higher APACHE II score was iden-
tified as an independent risk factor in all the
studies examined. Thus, the APACHE II score
appears to be the best predictor of treatment
failure or death in patients with intra-abdomi-
nal infections, a conclusion that has been
echoed by Ohmann and Hau [120].
Higher APACHE II scores primarily identify
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patients with acute physiological changes in-
duced by infection and chronically impaired
physiological reserves. It is unclear how the se-
lection of antimicrobial therapy might be ex-
pected to impact clinical outcome in higher-risk
patients designated on this basis. It seems more
likely that the choice of antimicrobial therapy
would influence outcome if higher-risk pa-
tients were selected on the basis of the severity
of the intra-abdominal infection itself or, par-
ticularly, on the basis of the specific organisms
involved in the infection.
Traditionally, the source of the intra-abdom-
inal infection was believed to influence the risk
of treatment failure and death, as exemplified
by the low mortality rates of patients with per-
forated appendicitis [113,114,116,119]. How-
ever, in multivariate analyses, the source of the
infection has not proved to predict outcome in-
dependently. The lower risk of treatment fail-
ure and death in patients with perforated ap-
pendicitis probably reflects the relatively
young age and lack of comorbid conditions
typical of patients with this disorder.
There is evidence, however, that the suscep-
tibility patterns of the organisms involved in
the intra-abdominal infection influence the suc-
cess or failure of empiric antimicrobial therapy.
In a trial by Christou et al. [90], all patients hav-
ing at least one resistant organism isolated at
the time of initial intervention experienced
treatment failure. In another trial, Barie et al.
[95] found that a prolonged prestudy length of
hospitalization was an independent predictor
of failure. This risk factor may have identified
patients who had previous antimicrobial expo-
sure or who had postoperative peritonitis, and
would therefore be more likely to harbor or-
ganisms resistant to commonly used antimi-
crobials. In a retrospective review of five an-
tibiotic trials, Hopkins et al. [121] found that
the susceptibility of peritoneal isolates to the
initial empiric regimen also predicted treat-
ment success or failure. Finally, Montavers et
al. [122] reached a similar conclusion based on
a retrospective review of patients with postop-
erative peritonitis, and showed by multivariate
analysis that the presence of organisms resis-
tant to the empiric regimen was an indepen-
dent predictor of mortality. It is important to
note that none of these studies provided direct
evidence that any specific antimicrobial regi-
TABLE 14. INDEPENDENT RISK FACTORS FOR MORTALITY OR TREATMENT FAILURE IDENTIFIED BY MULTIVARIATE ANALYSES
Reference Mortality Treatment failure
[95] NR APACHE II scoreBarie, 1997 Prolonged prestudy length of hospitalization
[113] APACHE II score
Dellinger, 1985 Malnutrition NRAge
[114] APACHE II score APACHE II scoreHypoalbuminemia HypoalbuminemiaChristou, 1993 NYHA functional class Age
[115] APACHE II score NRBohnen, 1994 Corticosteroid therapy
APACHE II score
[116] Mannheim peritonitis indexHypoalbuminemia NRPucelli, 1996 Hypocholesterolemia
Preoperative organ impairment
APACHE II score
Unsuccessful operation
[117] Age NRWacha, 1999 Liver disease
Malignant disease
Renal disease
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men would improve outcome in the higher-risk
patients defined by these criteria. However,
these results do suggest that a common feature
of higher-risk patients is the presence of resis-
tant organisms. The Committee would specu-
late that many of these resistant organisms are
of nosocomial origin.
One final risk factor for failure that has been
increasingly emphasized in recent trials is an
inadequate initial source control procedure. An
unsuccessful operation was, in fact, found to be
a risk factor for death in the multivariate analy-
sis carried out by Wacha et al. [117]. Clearly,
no antimicrobial regimen can be expected to be
successful if there is ongoing contamination or
an uncontrolled infectious source within the
abdomen.
Selection of antimicrobial regimens. Consider-
ing that higher-risk patients with intra-abdom-
inal infections are more likely to fail because of
resistant organisms, it seems reasonable to rec-
ommend antimicrobial regimens with broader
coverage of gram-negative aerobic/faculta-
tively anaerobic organisms for use in these pa-
tients. However, as discussed previously, this
recommendation was not made on the basis of
convincing Class I evidence demonstrating 
that this approach improves outcome. In the
previous guidelines, Bohnen et al. [1] recom-
mended imipenem/cilastatin, a third-genera-
tion cephalosporin plus an antianaerobic agent,
an aminoglycoside plus an antianaerobic
agent, or aztreonam plus clindamycin for the
treatment of patients with more serious infec-
tions. To this list, the Committee has added
piperacillin/tazobactam, meropenem, the
fourth-generation cephalosporin cefepime plus
an antianaerobic agent, and ciprofloxacin plus
metronidazole (Table 15). Depending on the like-
lihood of infection due to Pseudomonas in these
higher risk patients, the doses of some antimi-
crobial agents, such as piperacillin/tazobactam,
may need to be increased to provide adequate
anti-pseudomonal coverage. An aminoglycoside
plus an antianaerobic agent is still included in
the list of recommended regimens, but it is im-
portant that the aminoglycoside be dosed ade-
quately to ensure rapid attainment of therapeu-
tic serum concentrations in higher risk patients.
Further, these patients may be at increased risk
for nephrotoxicity and ototoxicity due to these
agents.
Another potential approach to treatment of
higher risk-patients with intra-abdominal 
infections is to utilize two agents effective
against gram-negative aerobic/facultative
anaerobic organisms. The usual combination is
an aminoglycoside plus an extended spectrum
beta-lactam antibiotic. This approach was
tested directly in several prospective random-
ized controlled trials. In the largest compari-
son, Dupont et al. [70] compared piperacillin/
tazobactam alone against the combination of
piperacillin/tazobactam with amikacin in pa-
tients with severe community-acquired intra-
abdominal infections and hospital-acquired in-
tra-abdominal infections. The overall mortality
rate in this trial was 20%, attesting to the high
acuity of the patients enrolled. Although the
success rate with piperacillin/tazobactam
(51%) was lower than that observed in other
studies of intra-abdominal infections, it was
equivalent to that seen in the group receiving
combination therapy (51%). In another study,
imipenem/cilastatin alone was compared to
imipenem/cilastatin plus netilmicin in 78 pa-
tients with severe, diffuse peritonitis [68]. Pa-
tients with peritonitis due to appendicitis or
upper gastrointestinal perforations were ex-
cluded from this study. The success rate with
imipenem/cilastatin alone was 79% as com-
pared to the success rate of 92% using
imipenem/cilastatin plus netilmicin. This dif-
ference in outcome was of borderline signifi-
cance (p 5 0.09), and was likely explained by
an imbalance in the numbers of severely ill pa-
TABLE 15. RECOMMENDED ANTIMICROBIAL REGIMENS
FOR HIGHER-RISK PATIENTS WITH
INTRA-ABDOMINAL INFECTIONS
Single agents
Imipenem/cilastatin
Meropenem
Piperacillin/tazobactam
Combination regimens
Aminoglycoside (amikacin, gentamicin, netilmicin,
tobramycin) plus an antianaerobe
Aztreonam plus clindamycin
Ciprofloxacin plus metronidazole
Third/fourth-generation cephalosporin (cefepime, 
cefotaxime, ceftazidime, ceftizoxime, ceftriaxone)
plus an antianaerobe (clindamycin or
metronidazole)
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tients in the two groups. Many more of the pa-
tients who received imipenem/cilastatin alone
had high APACHE II scores compared to those
who received the combination regimen. Fi-
nally, one additional study of 79 clinically
evaluable patients found that patients treated
with ciprofloxacin plus metronidazole had a
significantly better clinical outcome than pa-
tients treated with the combination of cefo-
taxime, gentamicin, and metronidazole [69].
Mortality was also relatively high in this study,
suggesting that a higher-risk group of patients
had been enrolled. Overall, these studies did
not demonstrate that the routine addition of an
aminoglycoside to another agent effective
against aerobic/facultative anaerobic gram-
negative organisms improves outcome, and the
Committee recommends against this approach
in higher-risk patients with intra-abdominal in-
fections.
Enterococcal coverage. Depending on the etiol-
ogy and severity of the infection, Enterococcus
is isolated from 5–20% of patients with intra-
abdominal infections. Its importance as a
pathogen and the need for its routine treatment
remain controversial [74,80,81,90,95]. As de-
scribed previously, prospective trials did not
demonstrate any improvement in outcome
comparing antimicrobial regimens that cov-
ered this organism with those that did not.
Therefore, the Committee did not recommend
routine use of regimens providing enterococcal
coverage for most patients with intra-abdomi-
nal infections.
However, it is not clear that this recommen-
dation should be extrapolated to higher-risk
patients, particularly those with hospital-ac-
quired infections. As emphasized repeatedly,
prospective trials have primarily enrolled less
severely ill patients. Further, the incidence of
enterococcal infections among enrolled pa-
tients has tended to be low. For instance, in the
study by Röhrborn et al. [81], which was de-
signed specifically to test the need for routine
enterococcal coverage in patients with com-
munity-acquired intra-abdominal infections,
only 5% of the patients actually had Enterococ-
cus isolated at the time of the initial lapa-
rotomy.
Enterococcal infections may be more com-
mon in higher risk patients, and, as with other
resistant organisms, isolation of Enterococcus
may also identify patients at higher risk for
treatment failure. In the retrospective review
by Hopkins et al. [121], isolation of Group D
Streptococcus, presumably enterococci, was as-
sociated with the likelihood of failure, although
it was not clear that this was an independent
predictor of failure. However, in another mul-
tivariate analysis of data obtained from a
prospective trial, Burnett et al. [123] found that
the isolation of Enterococcus was indeed an in-
dependent predictor of failure. In this study of
330 patients, of whom 21% had positive cul-
tures for Enterococcus, the failure rate was 28%
among patients who had this organism, but
was 14% among patients who did not. These
authors also found that patients at risk for en-
terococcal infections were those who were of
advanced age, had higher APACHE II scores,
had longer hospital lengths of stay prior to de-
veloping the infection, had a postoperative in-
fection, or had a colonic or small bowel source
of infection. Enterococci did not tend to be iso-
lated from patients with infections resulting
from appendicitis. Thus, the risk factors for
having enterococcal infections were quite sim-
ilar to those that described higher-risk patients
in general.
Although there is no Class I evidence that
treatment of higher-risk patients with antimi-
crobials providing enterococcal coverage im-
proves outcome, the Committee believes that
this may be a reasonable approach, given the
correlation that exists between enterococcal iso-
lation and increased risk of treatment failure.
Thus, for higher-risk patients with intra-
abdominal infections, the Committee recom-
mends that consideration be given to the use
of a regimen covering Enterococcus, particularly
when patients are likely to harbor this organ-
ism because of a previous failure of antimicro-
bial therapy. The choice of the specific antimi-
crobial regimen would depend in part on the
enterococcal resistance patterns specific to the
particular institution.
Treatment of Candida. Intra-abdominal infec-
tions due to fungal organisms, particularly
Candida albicans, primarily occur in higher-risk
patients. Many of these infections develop in
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postoperative patients, and almost all develop
in patients who have already been heavily
treated with broad-spectrum antibiotics [124].
Invasive candidal infections in the abdominal
cavity are associated with high mortality rates,
despite utilization of antifungal agents. Unfor-
tunately, there are only limited prospective
data with which to evaluate different ap-
proaches to the prevention and management of
intra-abdominal infections due to Candida.
Early initiation of antifungal therapy appears
to be an important determinant of outcome in
patients with intra-abdominal candidal infec-
tions. Solomkin et al. [124] described 55 pa-
tients with Candida peritonitis, and noted a 
progression of disease from infection of the
peritoneal cavity only, to colonization and in-
fection of multiple sites, to the eventual devel-
opment of candidemia and widespread, diffuse
candidiasis. Patients who did not receive anti-
fungal therapy until they developed positive
blood cultures were likely to fail treatment and
to die of the infection.
Although patients with Candida peritonitis
clearly have an established infection requiring
antifungal therapy, Candida is also isolated
from the peritoneal cultures of patients who are
colonized, but not infected with this organism.
Calandra et al. [125] examined a series of 49 pa-
tients with positive peritoneal cultures for Can-
dida, to determine what clinical characteristics
predicted the need for antifungal therapy.
These authors found that patients with recur-
rent gastrointestinal perforations and those
with postoperative infections following surgi-
cal management of acute pancreatitis were at
high risk for having an invasive candidal in-
fection requiring treatment. Patients with
heavy or increasing growth of Candida in semi-
quantitative cultures of peritoneal fluid were
also likely to need systemic antifungal therapy.
Based on these clinical findings, Eggiman et
TABLE 16. SUMMARY OF PROSPECTIVE RANDOMIZED CONTROLLED TRIALS OF ANTIFUNGAL
AGENTS FOR THE TREATMENT OF PATIENTS WITH INTRA-ABDOMINAL INFECTIONS
Number of Number of Reported APACHE
Antifungal patients evaluable success ITT Quality II
Reference agents enrolled patients rate analysis Mortality score scoring?
Prophylactic
[126] fluconazole 25 23
4 96%1,2 30% 13
Eggiman,
400 mg qd
1999 No prophylactic
antifungal agent 24 204 65%
1,2 50% 13
Fluconazole
400 mg, then 84 25%5,6 63% 21
200 mg qd
Amphotericin B NR NR 1
1–1.5 mg/kg qod
1 94 56%5,6 33% 20
5-Flucytosine
2.5 g tid
1Patients who failed therapy were those who developed Candidaperitonitis. Success rates were 83% in the fluconazole
group and 65% in the placebo group if any candidal infection was considered a treatment failure.
2The difference between the groups was statistically significant (p 5 0.02), in favor of the fluconazole group. The dif-
ference between groups was not statistically significant for the development of any candidal infection.
3No data were provided, but the result of the ITT analysis was stated to confirm the significant difference between the
groups with respect to the development of Candida peritonitis.
4The values represent the numbers of patients enrolled because of Candida peritonitis. A total of 36 patients were 
enrolled in each group because of any type of candidal infection.
5Success rates are based only on patients reported as clinically cured of  Candida peritonitis. Additional patients with
Candida peritonitis were considered improved, and could have been considered successfully treated, but their numbers
were not reported.
6Success rates in all treated patients, not just those with  Candida peritonitis, were 67% in the fluconazole group and
69% in the amphotericin B plus 5-flucytosine group.
[127]
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al. [126] undertook a prospective randomized
controlled trial of empiric fluconazole therapy
to prevent the development of invasive intra-
abdominal candidal infections in higher-risk
patients. The study population was restricted
to critically ill patients with recurrent gastroin-
testinal perforations or other postoperative in-
fections. Candidal peritonitis developed in
only one of the 23 clinically evaluable patients
treated with fluconazole, but in seven of the 20
clinically evaluable patients who received a
placebo. This difference was statistically sig-
nificant. Overall, 30% of the patients random-
ized to empiric therapy with fluconazole died,
as opposed to 50% of those in the placebo
group. Although this difference was not statis-
tically significant, four of the 10 deaths in the
latter group were directly attributed to com-
plications of Candida peritonitis (Table 16).
There is some controversy regarding the an-
tifungal agent of choice for patients with con-
firmed intra-abdominal candidal infections.
The efficacy of fluconazole for the treatment of
these infections was fortuitously demonstrated
in the data of Eggiman et al. [126], since 40%
of the patients who received fluconazole al-
ready had a candidal infection, as evidenced by
isolation of Candida from cultures of peritoneal
fluid obtained at the time of study entry.
Nonetheless, another trial questioned the use
of fluconazole for the treatment of candidal
peritonitis. This prospective randomized con-
trolled trial compared fluconazole with am-
photericin B and 5-flucytosine for the treatment
of critically ill patients with candidiasis from
any source. Seventeen of the 72 evaluable pa-
tients in this trial had Candida peritonitis. Two
of the eight patients (25%) treated with flu-
conazole were cured, as compared to five of the
nine (56%) treated with amphotericin B and 5-
flucytosine (Table 16). These results did not
reach statistical significance because of the
TABLE 17. GUIDELINES FOR ANTIMICROBIAL THERAPY FOR THE HIGHER-RISK PATIENT
1. In patients with intra-abdominal infections, treatment failure and death is associated with patient-related risk
factors such as advanced age, poor nutritional status, a low serum albumin, and preexisting medical
conditions, especially cardiovascular disease. A higher APACHE II score is the most consistently recognized
risk factor for both death and treatment failure (Level 1).
2. Disease- and treatment-related risk factors, including a nosocomial origin of infection, the presence of resistant
pathogens, and the lack of adequate source control, are associated with treatment failure and death (Level 2).
3. Patients at higher risk for failure (particularly from non–community-acquired organisms) should be treated
with an antimicrobial regimen having a broader spectrum of coverage of gram-negative aerobic/facultative
anaerobic organisms (Level 3):
Single agents:
Imipenem/cilastatin
Meropenem
Piperacillin-tazobactam
Combination regimens:
Aminoglycoside plus antianaerobe
Aztreonam plus clindamycin
Ciprofloxacin plus metronidazole
Third/fourth generation cephalosporin plus antianaerobe
4. Routine addition of an aminoglycoside to other effective gram-negative agents such as imipenem/cilastatin,
piperacillin/tazobactam, or third- or fourth-generation cephalosporins, is not recommended (Level 2).
5. High-risk patients likely to fail due to Enterococcus, such as those of advanced age, with higher APACHE II
scores, a colonic or small bowel source of infection, a postoperative infection, or a nosocomial origin of
infection, may benefit from the use of a regimen covering this organism (Level 3).
6. Addition of empiric antifungal therapy with fluconazole is reasonable for patients with postoperative intra-
abdominal infections at high risk for candidiasis (Level 2). For patients with established Candida peritonitis,
antifungal therapy with amphotericin B may be preferable to use of fluconazole, but the choice of therapy
must be influenced by the risk of toxicity in a given patient (Level 3).
7. Patients with tertiary peritonitis are likely to harbor difficult to eradicate organisms, such as coagulase-negative
staphylococci, enterococci (including vancomycin resistant enterococci), multiply-resistant gram-negative bacilli,
and yeast (Level 2). Empiric therapy should be directed at organisms likely to be present based on the
patient’s history of previous antimicrobial therapy and local patterns of infectious organisms and resistance.
Empiric therapy should be modified according to definitive culture results (Level 3).
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small number of patients in this subset analy-
sis, but they raised some concern with regard
to the efficacy of fluconazole in a particularly
severely ill population of patients with intra-
abdominal candidal infections.
Overall, based on this limited evidence, the
Committee recommends empiric use of flu-
conazole in patients who are at high risk for
failure due to candidal infections in the ab-
domen. Examples of such patients include
those with recurrent gastrointestinal perfora-
tions or anastomotic leaks, and those who de-
velop or have persistent infections after opera-
tive management of acute pancreatitis. For
critically ill patients with established candidal
peritonitis, there is a suggestion that ampho-
tericin B may be preferable to fluconazole.
However, additional considerations, particu-
larly the risks of toxicity in a given patient,
must also be factored into the decision to select
a specific antifungal agent.
Tertiary peritonitis. Patients who have persis-
tent intra-abdominal infections after multiple
therapeutic attempts are described as having
tertiary peritonitis. There are relatively few
data to guide treatment decisions in this group
of patients. Typically, these patients are in-
fected with resistant organisms such as coagu-
lase–negative Staphylococcus, enterococci, in-
cluding those resistant to vancomycin,
multiply resistant gram-negative bacilli, and
fungal organisms, including many that are re-
sistant to fluconazole [128,129]. Open abdomi-
nal techniques have been used in some of these
patients as a means of achieving source control,
but the efficacy of such methods has not been
proved definitively.
The consensus of the Committee is that an-
timicrobial therapy needs to be individualized
for patients with tertiary peritonitis. Empiric
antimicrobial therapy should be directed at the
nosocomial organisms likely to be causing the
infection, based on individual and institutional
experience. The choice of agents should also re-
flect the resistance patterns of likely pathogens,
the patient’s history of prior antimicrobial ex-
posure, and the results of the Gram stain of in-
fected peritoneal fluid, when available. Empiric
therapy is adjusted subsequently according to
the final culture results.
Patients suffering from tertiary peritonitis
have an overwhelming failure of host defense
mechanisms [128–130]. Treatment failure is
common, and many of these patients eventu-
ally succumb to the effects of multiple organ
failure, whether or not the intra-abdominal in-
fection has been controlled. This has led some to
speculate that antimicrobial therapy should not
be used in patients with tertiary peritonitis.
However, in the absence of data establishing a
benefit of not treating pathogenic microorgan-
isms, the Committee concurs with the opinion of
Solomkin [130] that specific antimicrobial ther-
apy is warranted for these very challenging 
patients. Guidelines for the identification and
treatment of higher-risk patients with intra-ab-
dominal infections are listed in Table 17.
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APPENDIX: EXPLANATIONS OF HEADINGS 
AND ABBREVIATIONS FOUND IN TABLES 3–8
Headings
Antimicrobial agents or antifungal agents. Only the initial doses of antimicrobials are indicated.
If aminoglycoside dosing was subsequently modified according to monitoring of serum amino-
glycoside concentrations, this is indicated in the footnotes. Dosing modifications of other agents
are also indicated in the footnotes.
Number of patients enrolled. These numbers represent all patients randomized to study treat-
ment. If patients were enrolled for diagnoses other than intra-abdominal infections, this is indi-
cated in the footnotes. The inclusions of patients less than 14 years of age are indicated in the
footnotes.
Number of evaluable patients. These numbers represent the number of clinically evaluable pa-
tients actually used in determining success rates. Inclusions of patients in the clinically evalu-
able population who did not have complicated intra-abdominal infections, that is, those who
did not undergo primary source control procedures, are indicated in the footnotes.
Reported success rate. Success rates are based on clinically evaluable patients with intra-ab-
dominal infections. In studies reporting treatment results other than success or failure, success
rates were calculated after counting all patients classified as “improved” as successfully treated,
and excluding patients classified as having indeterminate outcomes. If several success rates were
reported, the rates indicated are those determined at the latest time point for which follow-up
was complete. If the investigators did not report an overall success rate, it was calculated as best
as possible using the data provided in the publication. Except for these exceptions, the success
rates reported by the investigators were accepted as final, regardless of the criteria used to de-
fine success and failure.
Percentage of patients with sSSI. If information was provided in the publication, the percentages
of patients who developed sSSI were determined, whether or not these infections were consid-
ered to represent a failure of therapy.
Success rate excluding isolated sSSI. The reported success rates were recalculated after counting
patients who failed therapy only because of isolated sSSI as successfully treated. N/A indicates
that the calculation could not be performed because the number of patients who failed therapy
because of isolated sSSI could not be determined.
ITT analysis. Only analyses reported by the authors are included.
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Mortality. These values were based on the clinically evaluable populations unless otherwise
indicated.
Percentage of patients with hollow viscus injury and percentage of patients with appendicitis. These
values were based on the clinically evaluable populations unless otherwise indicated.
Quality score. These values were determined according to the procedure of Jadad et al. [22].
N/A is indicated for class II studies, which were not graded.
APACHE II scoring? “Yes” indicates that scoring was performed. If mean APACHE II scores
were reported, they are included in the table.
Specified treatment duration. The duration of treatment specified by the protocol.
Duration of antimicrobial therapy. The average length of time patients actually received antimi-
crobial therapy.
Complicated infection per IDSA criteria? “Yes” indicates that the authors used the criteria of
Solomkin et al. [6] or similar criteria to determine enrollment and inclusions of patients in the
clinically evaluable populations. “No” indicates that patients who did not have intra-abdominal
infections or did not undergo primary source control procedures were considered clinically
evaluable, or that patients with negative peritoneal cultures were included in the clinically evalu-
able populations. “Probably not” indicates that all patients had intra-abdominal infections and
positive peritoneal cultures, but that some patients may have had localized infections or intra-
abdominal contamination not requiring therapeutic antimicrobial therapy. Examples of such pa-
tients include those with localized, non-perforated appendicitis and those with recent gastro-
duodenal or traumatic enteric perforations.
Abbreviations
ITT Intention-to-treat
NR Not reported
N/A Not applicable
IDSA Infectious Disease Society of America
NYHA New York Heart Association
sSSI Superficial surgical site infection
